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Zusammenfassung
Die Menschheit ist vielfältigen chemischen Wirkstoffen ausgesetzt – zum Beispiel durch Kos-
metika und Pharmazeutika sowie durch viele andere chemische Quellen. Es wird angenom-
men, dass diese stetige Exposition mit Chemikalien gesundheitliche Beeinträchtigungen bei
Menschen hervorruft. Zudem haben Regulierungsbehörden aus Europa und den USA fest-
gestellt, dass es ein Risiko gibt, welches mit der kombinierten Exposition durch mehrere
Chemikalien im Zusammenhang steht. Mögliche Kombinationen von Tausenden Wirkstof-
fen zu testen, ist sehr zeitaufwendig und nicht praktikabel. Das Hauptanliegen dieser Arbeit
ist es, die Probleme von Off-target-Effekten chemischer Strukturen zu benennen – mit den
Mitteln der Chemieinformatik, der strukturellen Bioinformatik sowie unter Berücksichtigung
von computerbasierten, systembiologischen Ansätzen.
Diese Dissertation ist in vier Hauptprojekte eingeteilt, die jeweils für vier unterschiedliche
computerbasierte Simulationsmethoden stehen, um verschiedene Ebenen toxikologischer
Untersuchungen zu adressieren.
Im Projekt I (Kapitel 3) wurde ein neuartiger Ensemble-Ansatz basierend auf der strukturellen
Ähnlichkeit von chemischen Wirkstoffen und Bestimmungen von toxischen Fragmenten im-
plementiert, um die orale Toxizität bei Nagetieren vorherzusagen. Dieser Ansatz brachte
überzeugende und konsistente Ergebnisse, die bereits vorhandenen kommerziellen sowie
anderen bekannten Methoden überlegen sind. Im Projekt II (Kapitel 4) wurden – auf der
Grundlage von Daten des Tox21 Wettbewerbs – unterschiedliche Machine-Learning Mod-
elle entwickelt und verglichen, um die Komponenten vorherzusagen, die in den toxikologis-
chen Stoffwechselwegen mit Zielmolekülen interagieren. Die vorgestellten Methoden dieser
Studie können von Regulierungsbehörden genutzt werden, um im großen Umfang die Toxiz-
ität von target-spezifischen Wirkstoffen vorherzusagen.
In Projekt III (Kapitel 5) wird ein neuartiger Ansatz beschrieben, welcher das dreigliedrige
Konzept aus computerbasierter Systembiologie, Chemieinformatik und der strukturellen-
Bioinformatik nutzt, um Medikamente zu bestimmen, welche das metabolische Syndrom
hervorrufen. Zwei unterschiedliche, neuartige Mechanismen für das medikamenteninduzierte
Fettleber-Syndrom wurden identifiziert und computerbasiert validiert.
vii
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In Projekt IV (Kapitel 6) wurde in silico ein Screening Protokoll entwickelt, welches die struk-
turelle Ähnlichkeit, die pharmakophorischen Eigenschaften und die Überprüfung von com-
puterbasierten Docking Studien berücksichtigt. Dieser Ansatz führte zur Identifikation neuer
Bindungsstellen für Acyclovir in der Peptid-Bindungsstelle für das HLA-spezifische Allel.
Solche spezifischen Verbindungen von Medikamenten und dem HLA-spezifischen Allel verur-
sachen immun-modulierte unerwünschte Medikamentenwechselwirkungen.
Der Gesamtbeitrag dieser Arbeit beinhaltet die Entwicklung unterschiedlicher computer-
basierter Methoden mit speziellen chemieinformatischen Ansätzen, welche erfolgreich einge-
setzt werden können, um die Probleme von Off-target Effekten auf unterschiedlichen Ebenen
des Systems zu verstehen.
Schlagwörter: Toxizität Vorhersage, Maschinelles lernen, Cheminformatik, toxischen Frag-
menten, computerbasierter Systembiologie,
Abstract
Exposure to various chemicals agents through cosmetics, medications, preserved food, en-
vironments and many other sources have resulted in serious health issues in humans. Ad-
ditionally, regulatory authorities from Europe and United States of America have recognized
the risk associated with combined exposure to multiple chemicals. Testing all possible com-
binations of these thousands of compounds is impractical and time consuming. The main
aim of the thesis is to address the problem of off-targets effects of chemical structures by ap-
plying and developing cheminformatics, structural bioinformatics and computational sys-
tems biology approaches.
This dissertation is divided into four main projects representing four different computational
methods to aid different level of toxicological investigations.
In project I (chapter 3) a novel ensemble approach based on the structural similarity of the
chemical compounds and identifications of toxic fragments was implemented to predict ro-
dent oral toxicity. This approach showed powerful and consistently best performance over
available commercial as well as other public methods.
In project II (chapter 4) different machine learning models were developed and compared
using Tox 21 challenge 2014 data, to predict the outcomes of the compounds that have the
potential to interact with the targets active in toxicological pathways. The methods proposed
in this study can be used by the regulatory agencies to access the toxicity of these target spe-
cific compounds in large scale.
In project III (chapter 5) a novel approach integrating the trio concept of ’computational
system biology, cheminformatics and structural bioinformatics’ to predict drugs induced
metabolic syndrome have been described. Two different novel mechanisms for drug induced
fatty liver syndrome has been proposed and computationally validated.
In project IV (chapter 6) a in silico screening protocol was established taking into the struc-
turally similarity, pharmacophoric features and validation using computational docking stud-
ies. This approach led to the identification of novel binding site for acyclovir in the peptide
ix
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binding groove of the human leukocyte antigen (HLA) specific allele. Such specific binding
of drugs to the specific HLA alleles results in immune-mediated adverse drug reactions.
The over all contribution of the thesis includes development of different computational meth-
ods that can successfully be applied to address the problems of off-targets effects at various
levels of system inference.
Keywords: Toxicity prediction, machine learning, fatty liver, system biology, similarity search-
ing, cheminformatics
Chapter 1
Introduction
”Poison is in everything, and no thing is without poison. The dosage makes it either a poi-
son or a remedy”. Almost 500 years ago, Paracelsus acknowledged that the subtle distinction
between whether a given chemical compound acts as a medicine or poison is often deter-
mined by the dose as well as amount of time at which it is given 1. However, it is only by the
twentieth century Paracelsus understanding of dose-dependent toxicity profiles of chemical
compounds manifested a new definition in terms of system level understanding of toxicity
in modern science 2. From the science of poisons and intoxication, toxicology and its scope
has broadened and developed with time, and currently has been regarded as the ‘science of
safety’ and ‘personalized therapeutic administration’ 2. In summary, toxicology is a transla-
tional science, transferring knowledge from basic science into practical applications to safe
guard public health and the environment 2.
Humans are exposed to various chemicals agents through cosmetics, pharmaceuticals and
many other sources. Exposure to chemicals is suspected as playing a main role in develop-
ment of some adverse health effects in humans. Mechanism-based prediction and evalua-
tion of chemical compound’s toxicity constitute an evolving science whose development is
critical to drug discovery, development and regulatory evaluation 3. The vision involved in
this outlook is to make advances in human therapeutics available while protecting public
health.
There are different ways a toxic response is associated with chemical compound (e.g drugs,
environmental chemicals). Toxic effects are sometimes direct and predictable following an
overdose of the chemical compounds. This effect can be due to direct association between
presence of certain toxic patterns (fragments) in the chemical compounds and toxicity 4; on
the other hand it may be sometimes due to changes in the metabolism of the compound
resulting in toxic metabolites 5. Additionally this direct and predictable toxic response may
be mediated by metabolites and may be pharmacolgic or immunologic in nature. It is also
1
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observed that sometimes toxic response can be direct and yet unpredictable either following
one dose or just a few doses. These effects are often termed as ’the idiosyncratic response’.
They may appear only in a specific group of people and often there is no good prediction for
their occurrence 1.
Chemical compounds and toxic effects can be well spread including hierarchically levels con-
necting one functional domain to the next, starting with initial interactions with molecular
targets to organelles (such as mitochondria) to cells and to organs, resulting in detectable as
well as measurable toxic response 3. Often chemical compounds (drugs) along with their de-
sired therapeutic effects can also result in off-target effects and systemic adverse reactions,
due to several interactions with other molecular targets in the target network.
Rapidly evolving data resources from various levels of information such as chemistry, struc-
tural bioinformatics, cheminformatics, metabolomics, proteomics, genomics and their in-
terconnections has been the foundation of the predictive science. The growth in the field
of in silico toxicity prediction also known as computational toxicology has led to the devel-
opment of methods and models for prediction of toxicological endpoints, clinical adverse
effects and metabolism of pharmaceutical substances 6. Additionally regulatory authorities
from Europe and the United States of America have realized the risk associated with com-
bined exposure to multiple chemicals. Testing all possible combinations of these thousands
of compounds is impractical and time consuming. Thus computational toxicity prediction
methods integrate all relevant information on a compound and its structural or substructural
analogs to make preliminary assessments of potential toxicity. Furthermore, along with the
identification of the chemical determinants that are associated with observed off-target ef-
fect, computational methods can also help to investigate the underlined mode of action or
molecular mechanism 7 .
This thesis focuses on the development of in silico methods for prediction of toxic outcomes
in chemical compounds. The thesis envisages a global view in response to toxicity profiles of
chemical compounds as well as local (specific) consideration on the mechanism and path-
way level. For example, a drug or a chemical compound might interact with a molecular
target which can result in interactions with multiple molecular targets including both ther-
apeutic as well as off-target with different affinities. In this process, consequently it can ac-
tivate different signaling pathways or interact with functional pathways. Additionally, such
interactions at cellular level can produce toxic effects on certain organs. This can be further
extended to the adverse drug reactions (ADRs) profile of population sharing similar toxico-
logical pathways or network. A schematic diagram of such view is represented in the figure
1.1 .
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FIGURE 1.1: Different layers of information considered in this thesis to address off-targets
effects The figure is inspired from 6 and represents drugs interacting with different targets,
can effects several pathways resulting in off-targets effects on specific organs, sometimes
leading to specific ADRs profile.
1.1 Aim of the thesis
The dissertation study represented here tries to address the following major questions :
1) Can we predict compound toxicity based on rules that define the relationship of structure
and toxicity from existing data ?
2) Can we derive quantitative correlations between compound structure and off-target effect
using machine learning methods and rationally selected molecular descriptors, interacting
with targets involved in toxicological pathways ?
3) Can we integrate the concepts of kinetic modeling of metabolic network, structural bioin-
formatics and cheminformatics to predict drugs with fatty liver profiles and the underlying
mechanism of drug induced fatty liver ?
4) Can drugs having similar structural and therapeutic classes bind to specific HLA allele in
similar manner ?
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1.2 Outline of the thesis
The thesis structure is organized as follows:
Chapter 1, introduces the reader to the subject and aims of this PhD dissertation.
Chapter 2 provides the important ‘theoretical background’ of some key concepts necessary
to understand the discussed topics and results in this thesis.
Chapter 3 describes a novel computational method for the prediction of rodent acute oral
toxicity. The uniqueness of this approach includes identification of certain toxic patterns
along with similarity approach to predict toxic outcomes only based on chemical structures.
Additionally a natural product database is reported along with toxicity profiles as well as
pathways associated with the natural compounds.
Chapter 4 describes the development of different computational models to identify chemi-
cals that could be active in toxicological pathways.
Chapter 5 represents a novel integration of the trio ’computational systems biology , struc-
tural bioinformatics and cheminformatics’ approaches to predict drugs involved in metabolic
syndrome and the possible underlying mechanism.
Chapter 6 describes a virtual screening protocol and computational method to identify ap-
proved drugs that can bind to HLA specific alleles in the context of collaboration resulting in
the in silico identification of experimentally verified approved drug that binds to HLA specific
alleles.
Chapter 7, summarizes the main results and important finding in this thesis. Concluding
remarks for the impact of this dissertation are also highlighted along with possible areas for
future studies.
1.3 Publications included in this thesis
This thesis consists of the following publications. The author’s contribution to each of the
publication is stated below.
Chapter 3 is based on
1. Drwal M, Banerjee P, Dunkel M, Wettig M and Preissner R
’ProTox: A web server for the in silico prediction of rodent oral toxicity’ Nucleic Acids
Res. 42(Webserver issue W1) : W53-58.
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(The author was involved in design of the project. The author contributed equally in
data preparation and analysis, similarity method development and calculations of the
descriptions. Fragmentation method was implemented by the author. Additionally,
author was involved in the design of the web-server)
2. Banerjee P, Drwal M and Preissner R
Identification of chemical fragments involved in toxicity (in prep)
(The author has designed and conceived the study. Performed all the analysis, devel-
oped the method and written the manuscript)
3. Banerjee P, Erehman J, Gohlke B.O, Wilhelm T, Preissner R and Dunkel M
Super Natural II: A database of natural products Nucleic Acids Res.(Database issue)
(2014)
(The author was involved in design of the study. Generation of data and analysis. In-
cluded toxicity prediction part to the database. Involved in the development of the
database and written the manuscript).
Chapter 4 is based on
1. Drwal MN, Siramshetty VB, Banerjee P, Goede A, Preissner R and Dunkel M (2015)
Molecular similarity-based predictions of the Tox21 screening outcome Front. Env-
iron. Sci. 3:54
(The author introduced the concept of KNIME based modeling in this project and ini-
tiated the machine learning model approach. The author was equally involved in the
data preparation and analysis, generation and validation of the predictive models, cal-
culations and selections of the descriptors.)
2. Banerjee P, Siramshetty VB, Drwal M and Preissner R (2016)
Computational methods for prediction of in vitro effects of new chemical structures
using Tox21 challenge data J Cheminform 8:51.
(The author equally conceived the study. Designed, developed and analyzed the ma-
chine learning models and chemical space analysis. Author was involved equally in the
manuscript writing process along with Siramshetty VB)
Chapter 6 is based on
1. Metushi I.G, Wriston A, Banerjee P, Gohlke B.O, English A.M, Lucas A, Moore C, Sidney
J, Buus S, Ostrov D.A, Mallal S, Phillips E, Shabanowitz J, Hunt D.F, Preissner R and
Peters B
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Acyclovir Has Low but Detectable Influence on HLA-B*57:01 Specificity without In-
ducing Hypersensitivity. PLoS ONE 10(5): e0124878 (2015).
(The author was involved with computational part of the study. The author along
with B.O Gohlke and R. Preissner conceived the study. The author analysed the phar-
mocophoric groups, equally involved in 2D similarity search strategy, performed the
molecular docking studies and analysis and written the computational part along with
pictures generation).
Chapter 2
Theoretical background
2.1 In silico toxicology
In silico toxicology, also referred as computational toxicology is a novel strategy in the field of
toxicological research which aims to establish mathematical models based on existing knowl-
edge for predictions of untested and possibly unsynthesised, compounds 2. One of the most
important features of computational toxicology is its high degree of integration of different
layers of informations linking computational systems biology, bioinformatics and chemin-
formatics methodologies. Given an ideal case, it is possible to establish the toxicity profiles
of chemical structures associated with known mechanism of action (MOA) or even better link
with an ’toxicological pathways’. However, if the toxic effect is the result of several different
mechanism working sequentially or simultaneously, then the reliable prediction based on
the chemical structure could be difficult 3 .
Computational toxicology is highly dependent on the quality as well as large amount of data.
Therefore, data extracted from standard experimental conditions can significantly reduce the
error associated with the predictions of the in silico models. Although computational toxi-
cology have developed recently, however the increase in publications in literature databases
(such as PubMed) over the last decade on topic as ’in silico’ and ’toxicity’ highlights their
growing importance. The funding for projects related to toxicity based research through
EU grants has been rising at alarming rate such as EU-ToxRisk (http://www.eu-toxrisk.
eu/, COSMOS - a European Union project developing methods for determining the safety of
cosmetic ingredients for humans, without the use of animals, using computational models
(http://www.cosmostox.eu/), and NOTOX (http://notox-sb.eu/). On the other hand,
TOXCAST (http://www.epa.gov/chemical-research/toxicity-forecasting and Tox21
(http://www.epa.gov/chemical-research/toxicology-testing-21st-century-tox21)
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platforms promoted by the US Environmental Protection Agency (EPA) in support of in sil-
ico toxicology contributed to the paradigm change away from animal testing to alternative
methods by combining system biology, molecular biology and computational methods.
2.2 Cheminformatics
The analysis and methods developed in this thesis are based on the scientific discipline chem-
informatics or Chemoinformatics, also sometime refers as chemical informatics or molecu-
lar informatics. Though there have been some disagreement over the name within the com-
munity, however ’cheminformatics’ is favored by the Journal of Cheminformatics (http://
jcheminf.springeropen.com/) . Chemoinformatics is an emerging science that concerns
the computational storage, retrieval and reasoning about chemical information 8 . Chemin-
formatics was first formally defined as the use of information technology and management
has become a critical part of the drug discovery process. Cheminformatics is the mixing of
those information resources to transform data into information and information into knowl-
edge for the intended purpose of making better and faster decisions in the area of drug lead
identification and organization as stated by Brown in 1998 9. This definition as termed by an
industrial pharmaceutical scientist was obviously based towards the pharmaceutical appli-
cations. However with the advancement of research in the areas of chemistry, computational
chemistry, molecular modeling, computer science and statistics, supports that recent chem-
informatics based scientific research appeals to almost any area of chemical research, bio-
logical research, toxicological research and systems biology 10. Cheminformatics addresses a
broad range of problems in chemistry and biology; however, the most commonly known ap-
plications of chemoinformatics approaches have arguably been in the area of drug discovery,
where cheminformatics based methods have tried to establish robust relationships between
a chemical structure and its physical or biological properties 8 .
2.2.1 Molecular representations
Large amount of chemical as well as biological data are stored in databases. Some of these
databases are publicly available while some are commercially 11 . They contains large num-
ber of compounds ranging from several hundred thousands to million of entries. It is nev-
ertheless possible to search data in these databases and retrieve the information in seconds.
In this section, some of the most commonly used methods in cheminformatics to represent
molecular structures and used in the creation of structural databases are described.
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2.2.1.1 Molecular graph
Molecular graph is an usual way to store chemical structures in a computer. Graph theory has
been well-established in the area of mathematics which has found its recognition not only in
chemical or biological sciences but in also many other areas, such as computer science 13.
Chemical structures can be effectively represented as labeled graph 12. A graph consist of
nodes and edges. In a molecular graph each atom is associated with a node and each bond
with an edge. The nodes and edges in a molecular graph may have properties associated with
them. That is, the nodes may represent the atomic number, symbol where as the edge rep-
resents the bond order. These properties are important while performing some operations
using the molecular graph. As these molecular graphs can be constructed in more than one
ways, it is therefore important to have methods that can determine whether two molecular
graph are identical. Theoretically, this problem is known as graph isomorphism 13 .
2.2.1.2 SMILES
SMILES (Simplified Molecular Input Line System) is an unambiguous and reproducible method
for represent molecules computationally developed by Wiswesser in the year 1985 14. This
method represent molecule structure as a linear string of symbols based on certain pre-
defined rules. SMILES are based on hydrogen suppressed graph based on the assumption
that hydrogens contributes to atom’s lowest normal valence. All the non-hydrogen atom in a
SMILES string are represented by their atomic symbols enclosed in square brackets. Formal
charges are assigned as + or - ; where as aromatic atoms are specified using the lowercase
atomic symbols. Single, double , triple and aromatics bonds are represented as ’-’, ’=’, ’ #’ and
’:,’ respectively. Cyclic structures are represented by breaking a ring at a single or aromatic
bond and numbering the atoms on either side of the break with a number. For example,
benzene (cyclohexane) can be represented as SMILES string C1CCCCC1 15.
SMILES are efficient ways for storage and retrieval compounds across multiple computer
platforms. SMILES algorithm can detect most of the aromatics compounds with applied
Huckel’s rule, but do not account for the tautomers in the chemical structures. Therefore,
there can be more than one valid SMILES for chemical structures based on the algorithm
used to create them.
2.2.1.3 SMARTS
SMARTS (SMILES Arbitrary Target Specification) is an extension of SMILES that allows for
variability within the represented chemical structure. It encodes based on all the rules of
SMILES and additionally includes logical operators. such as ’AND’ (&), ’OR’ (,), and ’NOT’
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(), and special atomic and bond symbols that provide flexibility to chemical names. SMARTS
representation of molecules are often used for substructure searching 16 .
2.2.1.4 InChI and InChIKey
InChI (International Chemical Identifier) was developed and released in 2005 as open source
chemical structure representation algorithm with an aim to established a common platform
to unify searches across multiple chemical databases. It is maintained by the InChI Trust
(http://www.inchi-trust.org/. InChIKey is the hashed key version of InChI. The aim of
the InChIKey is to provide a unique representation of chemical structures that can be indexed
for searching in databases 17.
InChI is made up of several layers to represent different classes of information in a chemical
structure. The starting first two layers encodes general information like chemical formula
and connections between atoms 18. Additional layers encodes the information on stereo-
chemistry, tautomerism and isotopic information. The three sublayers represents the all
bond to non-bridging hydrogen atoms„ immobile hydrogen atoms and mobile hydrogen
atoms respectively 18. The algorithm behind InChI creation includes six normalization rules
taking into consideration of variable protonation and identification of tautomeric patterns
and resonances to establish an unique and consistent chemical structure representation 18.
InChIKey generates two blocks using a truncated SHA-256 cryptographic hash function based
on InChI. The keys contain a fixed length of 27 characters making sure there is a minimal
chance of two different molecules with the same hash key. Use of InChIKeys for comparing
molecules in different data bases were tested and obtained very low error rate 19.
2.2.1.5 Molecular fingerprints
Molecular fingerprints encodes the structural, pharmacophore or property descriptors in to
binary bit string format 20 . Each bit position accounts for the presence or absence of a given
pattern. The bit is set to ’1’, if a particular pattern is present in the molecule and set to ’0’ if
the pattern is absent 21. There are different molecular fingerprints types varying substantially
in their design and length. Mostly these fingerprints have fixed length, but not always. In
addition to the presence and absence of a given pattern, fingerprints also account for the
number of occurrences of the pattern in the molecule (e,g hydroxyl group or a benzene ring).
Molecular fingerprints representations are often used to search for molecules ’similar’ to a
query compound 22.
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2.3 Molecular descriptors
Molecular descriptors can represent both structural or physicochemical properties. Based on
1D; 2D and 3D co-ordinates of a chemical structures descriptors can encodes properties like
molecular weight, geometry, chemical formula, volume, surface areas, ring content, rotatable
bonds, interatomic distances, bonds, atom types, electronegativities, polarizabilities, sym-
metry, atom distribution, topological charge, functional group compositions, aromaticity.
solvation properties and many more 23. All these descriptors are computed using knowledge-
based, graph-theoretical methods, molecular mechanical or quantum-mechanical tools 23.
Higher information content encoded by these descriptors makes them extremely important
important and useful for model generation 24.
Some of the important descriptors used in this study are explained in details.
2.3.1 Functional groups
According to the International Union of Pure and Applied Chemistry, functional groups are
atoms or groups of atoms that have similar chemical properties across the range of various
chemical compounds 25. They are attached to a central backbone often called as scaffold or
chemotype defining its physical and chemical properties. As a consequence, the location and
nature of functional groups for a compound contains key information related to its activity 25.
There are different functional groups such as hydrocarbons, halogens, oxygen, nitrogen, sul-
fur, phosphorous, amides, alcohols, esters, ethers, nitro group, thiols etc 25.
Functional groups can either can be represented based on their atomic composition and
bonds or implicitly encoded by their general properties. To explain, it is often observed that
under physiological conditions carboxyl groups are often negatively charged. This property
is reflected in the structure of the functional group and this property corresponds to the most
important information on the biochemical activity of a given chemical compound 25. On the
other hand, the capacity to form hydrogen bonds can greatly influence a molecule’s prop-
erties. Hydrogen bonding interactions influence the electron distribution of neighboring
atoms and the site’s reactivity; this makes it an important functional property for protein-
ligand interaction 26.
2.3.2 Electronegativity and Partial charge
This descriptor encodes the charge distribution over an entire molecule. To assign partial
charges to individuals atoms a new method was developed by Gasteiger and Marsili (1980)
called a Partial Equalization of Orbital Electronegativity (PEOE) 27 .
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2.3.3 Octanol/water partition coefficient
LogP (logarithm of partition coefficient between n-octanol and water) is regarded as one of
the important molecular descriptors that has been successfully used in the field of drug de-
sign, virtual screening and several activities prediction methods 28.
2.4 Pharmacophore
A pharmacophore summarizes the steric and electronic features that are needed to ensure
the optimal supramolecular interactions with a specific molecular target structure to trigger
(or to block) its desired biological response 29. Pharmacophore is a purely abstract represen-
tation of molecules that accounts for common molecular interactions capabilities of a group
of compounds towards a given target. Some of the pharmocophoric descriptors used to de-
fine a pharmacophore are hydrogen bond donor, hydrogen bond acceptor, aromatic ring,
hydrophobic and many more 29.
The standard eleven pharmacophoric features available at Discovery Studio are listed below:
1. Hydrophobic features represents a groups of atoms that are not adjacent to any charged
atoms or electronegative atoms, but have surface accessibility including phenyl, cy-
cloalkyl, isopropyl and methyl.
2. Hydrophobic (aliphatic) features represents only aliphatic atoms.
3. Hydrophobic (aromatic) features represents only aromatic atoms.
4. Hydrogen bond acceptor features represents the sp or sp3 nitrogen and sp3 oxygen
or sulphur that have a lone pair and charge less than or equal zero. Additionally basic
amines that have a lone pair.
5. Hydrogen bond acceptor (lipid) features represents atom or groups of atoms like ni-
trogen, oxygen or sulphur that have a lone pair and charge less than or equal to zero.
6. Hydrogen bond donor features represents only atom or groups of atoms like non-
acidic hydroxyls, acetylenic hydrogens, thiols, NHs (except tetrazoles and trifluromethyl
sulfonamide hydrogens).
7. Negative charge features represents only atom or groups of atoms that have negative
charges not adjacent to a positive charge.
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8. Negative ionizable features represents atoms or groups of atoms that are likely be de-
protonated at physiological pH, such as trifluoromethyl sulfonamide hydrogens, phos-
phonic acids, sulfinic acids, phosphinic acids or caboxylic acids, tetrazoles, sulfonic
acids.
9. Positive charge features represents atom or groups of atoms that have positive charge
not adjacent to a negative charge.
10. Positive ionizable features represents atoms or groups of atoms that are likely to pro-
tonated at physiological pH, such as basic amines, basic primary amidines, basic sec-
ondary amidines, basic guanidines.
11. Ring aromatic features represents aromatic rings with five or six member atoms.
Ligand based pharmacophore model is based on the HipHop algorithm. The algorithm con-
siders the 3D spatial arrangements of the chemical features that are common between the
set of active ligands for a chosen target 29. The features are identified by a pruned exhaustive
search initiating with small sets of features and extending to large number of common fea-
tures. The molecules in the training set are evaluated on the basis of the types of chemical
features they contain, along with their ability to adopt a confirmation that allows the cho-
sen features to be superimposed on an optimal configuration 29. The number molecule that
need to be mapped with the common features in the training set is user defined. The resul-
tant pharmacophores are ranked based on the fit value as well as the maximum number of
the training set that matched with the given features. The pharmacophore model can be val-
idated with a external validation set which can contains both actives and in-actives and their
specificity and sensitivity can be evaluated 29.
2.5 Machine learning in computational toxicology
Machine Learning can be defined as a collection of computational approaches used in pre-
dictive science given a tagged datasets 30. Machine algorithms are generally developed in
computer science and other related disciplines and have found association with chemical
modeling by a process of diffusion. In general, datasets of molecular structures are tagged
based on their activity; like active and inactive and this information is utilized to model a
binary classification based on the selection of appropriate molecular descriptors 30. The se-
lection of the molecular descriptors can be categorized into two steps: firstly, the molecular
structures are classically represented in form of a molecular graph and is converted into fea-
ture vectors into the chemical space. Secondly, the features vectors are mapped with the
property of interest using a mathematical function 30. Usually, the mapping of these descrip-
tors is often learned by the machine learning algorithm which is later used to make decisions.
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Machine learning methods in the field of the cheminformatics have been widely used in the
areas of bioactivity and ADMET (Absorption, Distribution, Metabolism, Excretion and Tox-
icity) properties prediction 31,32. It has been demonstrated that models build on machine
learning methods which take into account large dimensional data are highly successful for
robust external predictions. Machine learning and pattern recognition has a long associa-
tion with chemistry counting back for more than four decades, such as in the field of spec-
troscopic data interpretation30.
Although there are multiple machine learning algorithms which has been used in the field of
predictive modeling, nevertheless in this thesis three most popular classification algorithm
were implemented ; Naive Bayes (NB), Random Forest (RF) and Probabilistic Neural Network
(PNN). All the three algorithms are explained in details in the chapter 4 .
Chapter 3
Development of a novel method for
prediction of rodent oral toxicity using
similarity and fragment based
approach
The drug discovery and development process implies the design and selection of compounds
for identified therapeutic molecular target (proteins) and optimization of these compounds
to enhance activity. However, many compounds synthesized during the lead optimization
phase have failed to successfully place into the market mainly due to the discovery of adverse
effects 7. Therefore, a critical priority in the process of drug development and safety assess-
ment conducted by the regulatory authorities includes the early screening and detection of
serious toxicological issues 7. Although, in vivo toxicology has been applied intensively for
identification of side effects induced by a drug, however it is found that this approach alone
cannot help to reduce the large failure rate in late-stage clinical trials 7. It is indeed impor-
tant to have methods that can be easily integrated into the early stage of the drug discovery
process using only ‘chemical structure’ of the compounds. Regulatory agencies like the U.S
Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have taken
initiative to improve the prediction of toxicity of new molecules in the drug discovery and de-
velopment pipelines 33. The Replace, Reduce, Refines (3R) principle (European partnership
for alternative approaches to animal testing ) has been able to encourage the development
and optimization of alternative methods including in vitro assays and in silico predictions in
recent years7.
In general, in silico toxicology can be defined as mathematical data analysis and develop-
ment of computational algorithms for the prediction of toxicological activity of a compound.
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A large number of in silico models have been developed which focus on different levels of
toxicity such as on system level, specific organs, biochemical mechanism or certain biologi-
cal processes 34. The U.S Environmental Protection Agency (EPA) has defined computational
toxicology (i,e in silico toxicology) as the‘’integration of modern computing and information
technology with molecular biology to improve agency prioritization of data requirements
and risk assessment of chemicals” 35.
This chapter describes the similarity and fragment based ensemble method developed to
predict the lethal dose (LD 50) values for oral toxicity in rodents using only the chemical
space 36.
3.1 Introduction
Animal trials have been used for over 60 years to evaluate toxic profiles of chemicals used as
medicines, cosmetics, food additives, industrials and agricultural chemicals 36. Use of ani-
mals in toxicity issues has been expensive, time consuming and associated with ethical con-
cerns. Thus, in silico prediction methods have found as an alternative approach and aim
to rationalize the preclinical drug development reducing the time and costs involved in ani-
mal experiments. The prediction method described in this section is based on the structural
similarity of compounds with known median lethal doses (LD50) values and incorporation
of identified fragments (structural alert) over-represented in toxic compounds, representing
a novel approach in toxicity prediction.This method was validated on an external evalua-
tion set and displayed a strong performance in terms of sensitivity, specificity and precision
of 76 %, 95 % and 75 % respectively. There are several commercial as well as freely avail-
able methods available for in silico toxicity prediction36. Some of the most used commercial
methods (softwares) in this domain are Discovery Studio’s TOPKAT (Toxicity Prediction by
Komputer Assisted technology; Accelrys, Inc., USA) (http://accelrys.com/) , ADMET Pre-
dictor (Simulations Plus, Inc., USA) (http://www.simulations-plus.com/) and ADME-
Tox Prediction (Advanced Chemistry Development, Inc., Canada) (http://www.acdlabs.
com/). Publicly available methods includes the Toxicity Estimation Software Tools (T.E.S.T)
(http://www.epa.gov/chemical-research/toxicity-estimation-software-tool-test)
developed by the U.S Environmental Protection Agency and AdmetSAR (web server), and are
mainly based on QSAR method. In spite of achieving good rates in toxicity prediction, QSAR
method have certain disadvantage for prediction of structurally novel compounds which was
not previously included in the training set 36. Moreover, in order to include new data into the
training set, redevelopment of new QSAR model is necessary. On the other hand implemen-
tation of similarity based methods are computationally inexpensive and new compound data
can be easily added to the training set 36. The essence of the similarity based method has been
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the assumption that molecules that are globally similar in structure should exhibit similar bi-
ological activity 37. That is molecules exhibit ‘neighborhood behavior’ 38. Similarity methods
have been successfully applied in the areas of compound selection for drug discovery, drug
repositioning studies and the prediction of drug-target interactions 39 . Thus, an approach
was designed based on integration of compound similarity (global) and fragment (local) oc-
currences for toxicity prediction.
3.2 Data preparation and processing
The data set used in this study was obtained from an in-house database of toxic compounds
’SuperToxic’ 40. The data set used for the method development consists of approximately 38
000 unique compounds with known oral LD 50 values in mg/kg body weight measured in
rodents. The complete dataset was standardized using Instant JChem 6.2.0 (January 2014),
ChemAxon. InCHI keys were calculated using the Discovery Studio version 4.2 and used to
remove duplicates in the dataset. In case a compound was reported with multiple LD 50 val-
ues, the lowest value was considered to represent the worst-case toxicity. Six toxicity classes
are defined according to the globally harmonized system (GHS) (https://www.osha.gov/
dsg/hazcom/global.html) of classification of labeling of chemicals as shown in the table
below:
Toxicity class Definition and LD 50 in mg/kg
I fatal if swallowed (LD 50 ≤ 5)
II fatal if swallowed (5 < LD 50 ≤ 50)
III toxic if swallowed (50 < LD 50 ≤ 300)
IV harmful if swallowed (300 < LD 50 ≤ 2000)
V may be harmful if swallowed (2000 <LD 50 ≤ 5000)
VI non-toxic (LD 50 > 5000)
TABLE 3.1: Toxicity classes with definition and LD 50 value range.
The distribution of training set molecules in different toxicity classes is provided below:
Toxicity class number of molecules
I 508
II 1886
III 6808
IV 20987
V 6343
VI 1985
TABLE 3.2: Number of compounds per toxicity class in the training set .
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3.3 Molecular fingerprints
Molecules were represented as molecular fingerprints for similarity calculation. For general
description of molecular fingerprints see in section 2.2.1.5 . Two different fingerprints : con-
catenated ’FP2’ and ’FP4’ fingerprints and Extended Connectivity Fingerprint (ECFP) 41 are
used in this study .
3.3.1 Path-based fingerprints (FP2 and FP4)
In a path-based fingerprint ’FP2’, small molecules linear fragments are indexed in to a binary
string format. These linear fragments length ranges from 1 to 7 atoms. However, single atom
fragments (e,g Carbon (C), Nitrogen (N), and Oxygen(O)) are ignored 36. In this kind of fin-
gerprints, the ring structures are not encoded as ring, but stored as single canonical linear
fragment. Each fragment is assigned as hash number from 0 to 1020 which is used to set a
bit in a 1024 vector. Where as in case of ’FP4’ fingerprints are created from a set of SMARTS
patterns which takes into account of functional groups. These two fingerprints were calcu-
lated separately using Open Babel library. Later, both the fingerprints were concatenated into
a single fingerprint which encodes the linear fragments as well as the functional groups for
each of the molecule in the dataset 36.
3.3.2 Circular fingerprints (ECFP)
Circular fingerprints are the representation of molecular structures by means of circular neigh-
borhoods. These fingerprints are a refinement of the Morgan algorithm 42, designed to iden-
tify the presence of particular substructures in a molecule. ECFP is generated by systemat-
ically recording the neighborhood of each non- hydrogen atom into multiple circular layers
up to a given user defined diameter; by using a fixed hash function 41. The results obtained
from these hash functions are mapped into integer indices. Each index of the fingerprint de-
notes the presence of a particular substructure. The substructures size represented by each
index depends on the number of layers used in the fingerprint generation process 41. The
layers are often termed as ’radius’. The substructures encoded in this fingerprints are not
predefined and generated in a molecule dependent manner and therefore, represents huge
number of different molecular features such as stereochemical information 41. They have of-
ten been used in the field of toxicity prediction and believed to provide more adequate results
for similarity searching 43. The ’ECFP’ fingerprint for this study was generated using the Java
library provided by JChem 6.1.3 (November 2013), ChemAxon. A separate Java program was
developed and the diameter for the creation of ECFP was considered as 4.
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3.4 Method
The prediction method described in this study is a combination of two approaches; similarity
and fragment-based approach. Each method is discussed in individual section below.
FIGURE 3.1: Ensemble method The workflow represents the data source as well as toxicity
classes used in this study. The integration of the global similarity scores and local fragment
based approach used for the toxicity prediction of the chemical compounds.
3.4.1 Similarity method
Similarity search calculation is performed based on the assumption of ‘similarity property
principle’ (i,e structurally similar molecules should have similar biological activity). Since,
interaction of a small molecule and a target protein is based on their structures, so small
molecules with similar structures are believed to interact in a similar manner with the pro-
tein target. The similarity score is computed comparing the two-dimensional (2D) molecular
fingerprints of the molecules as described in the sections 3.3.1 and 3.3.2. The similarity score
between two molecules represented as binary fingerprints is calculated using the Tanimoto
coefficient44 which gives the measure of overlapping bits between the two molecules.
The Tanimoto similarity (S AB) between two molecules A and B is given by:
SAB = c
a+b− c
Where a and b represents the number of bits set to 1 for molecules A and B respectively and
c represents the number of common bits set to 1 between them. The range of Tanimoto
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coefficient is between 0 to 1 where 1 indicates the maximum similarity where as 0 indicates
there is no similarity.
For example, the Tanimoto similarity between two molecules A and B represented as binary
vectors of length 10 can be calculated as shown below :
A = 0 1 0 1 1 1 1 1 1 0
B = 0 0 0 1 1 1 1 1 0 0
a = 7, b = 5 and c = 5
SAB = 5
7+5−5 = 0.71
Molecular similarity strategy is based on the evaluation of k-nearest neighbors (kNN) ap-
proach. Each compound in the evaluation set was compared to all the compounds in the
training set and average similarity of the three most similar compounds were considered to
predict toxicity class. In order to determine the best parameter for the similarity search, a
leave-out-cross-validation was carried out on the training set with two different fingerprints
separately.
FIGURE 3.2: Illustration of a kNN classification model For k=1, the classification of the
yellow query instance as a member of the red class; for k=3 it will be again assigned to the
red class based on a 2-1 vote. However in cass of k=5, the nearest neighbours are both green,
the model will classify it as a part of the green class with a 3-2 vote.
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3.4.2 Fragmentation method
In this section, a new method to predict the toxic effects of the chemical compounds based on
their local features (chemical fragments) has been proposed. The uniqueness of this method
is the ability to extract correlated sets of chemical substructures and their possible associa-
tion with certain toxicity class. This method is based on two steps: first fragmentation of the
molecules in the data set using two different types of fragmentation methods and second,
using propensity based statistical analysis of the fragments which are over represented in the
toxic classes.
The complete data set molecules were fragmented using fragmentation method called ROT-
BONDS and RECAP 45. The ROTBONDS fragmentation method cuts the molecule recur-
sively at its rotatable bonds. So more number of rotatable bonds in a molecule results in
more number fragments. Whereas, the RECAP is based on the rules of combinatorial chem-
istry and hence fragments created through this approach are easy to synthesis or joined (e.g
through amide linkage, ester bonds, quaternary nitrogen bonds). The unique fragments cre-
ated by ROTBOND and RECAP method were 37,251 and 45,712 respectively. After combin-
ing both ROTBONDS and RECAP fragments datasets and removing the duplicates, a total of
75540 fragments were created. Each fragment was mapped with an unique identifier and
the method by it was created as well their presence in the associated toxic class molecules.
For each of the fragments their occurance in individual toxic class was recorded using sub-
structure search and propensity score as well as a confidence score were calculated using the
formula described below
Let p1, p2, p3, p4, p5 and p6 represents respective toxic classes I, II, III, IV, V and VI
p1i= occurrence of fragment (i) in toxic class I
similarly for p2i, p3i, p4i, p5i and p6i
Let d1, d2, d3, d4, d5 and d6 are distribution of fragment (i) in respective toxic classes I, II, III,
IV, V and VI
Therefore equation (1),
d1i = p1i
p2i+p3i+p4i+p5i+p6i
Similarly for d2i, d3i, d4i, d5i and d6i are calculated for each fragment
Let T1, T2, T3, T4, T5 and T6 represents total number of fragments in toxic classes I, II, III, IV,
V and VI respectively.
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And dT1, dT2, dT3, dT4, dT5 and dT6 represents distribution of total number of fragments in
toxic classes I, II, III, IV, V and VI respectively,
Therefore equation (2),
dT 1= T 1
T 2+T 3+T 4+T 5+T 6
Similarly dT2, dT3, dT4, dT5 and dT6 are calculated,
So the final confidence score is given by,
Pscor e o f F r ag ment (i ) i n toxi c cl ass I = equati on(1)
equati on(2)
Similarly for PScore for each fragments for individual classes were calculated using the above
formula.
The Pscores were then normalized using Z score normalization. The Pscore of zero represents
absence of the fragment in a particular class and 1 represents the maximum occurrence. The
standard deviation curve for the Pscore was computed and threshold was considered to fur-
ther filter the most relevant fragments in the data set. The total number of fragment was
reduced to 32790. Finally, 7533 most toxic fragments representing the most toxic classes I, II
and III with high PSscore and absent in the less toxic classes IV, V and VI were chosen and
used as descriptor for the toxicity prediction model.
3.5 Results
Based on the comparison of the results of cross validation obtained using ECPF4, FP24 and
FP24 combined with fragments separately for the prediction method, the best performance
across all the toxicity classes was achieved by using ECFP4, followed by FP24 combined with
fragments and FP24. However, for the most toxic classes (class I, II and III) were predicted
more accurately by a consensus method taking FP24 and fragments into account, as shown
in table 3.3.
3.6 Performance evaluation
The prediction method was evaluated on an external independent validation set. The valida-
tion set represents approximately 5 % of the dataset used for prediction method with similar
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Sensitivity in % ECFP4 FP24 FP24 and fragments
Over all 70 68.8 69.1
Toxicity class I 33 37.4 41.0
Toxicity class II 48 42 50.9
Toxicity class III 60 59 62.2
Toxicity class IV 81 80.6 80
Toxicity class V 58 56.5 56.1
Toxicity class VI 41 39.4 39.3
TABLE 3.3: Performance of the prediction method in leave-one-out cross validation using
different features .
distribution of compounds for different toxicity classes. The method was evaluated on the
following measures based on number of true positive (TP), true negative (TN), false negative
(FN) and false positive (FP) as given below:
The true positive rate
Sensi t i vi t y = T P
T P +F N
The true negative rate
Speci f i ci t y = T N
T N +F P .
The positive predictive value
Pr eci si on = T P
T P +F P .
Coverage rate is defined as the percentage of compounds for which a prediction could be
made.
It was observed that consideration of the fragments increased the prediction rates for most
toxic classes as observed in the cross-validation see table 3.3 , in particular for toxicity class
I by 6 %, thus supporting the applicability of ensemble method. Furthermore, the coverage
also improved by approximately 2 % as shown in the table below.
Performance measure in % FP24 FP24 and fragments
Over all sensitivity 75.56 73.08
Sensitivity toxicity class 1 66.67 72.73
Sensitivity toxicity class 2 65.52 61.80
Sensitivity toxicity class 3 66.79 67.88
Specificity 95.11 94.62
Precision 75 73.50
Coverage 90.14 91.78
TABLE 3.4: Performance of the external validation set .
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3.7 Comparison with other methods
To further evaluate the performance of the prediction method, it was further compared to
commercial software TOPKAT (Accelrys Inc., USA) for oral rat LD 50 model and freely avail-
able software T.E.S.T (USA Environmental agency) oral rat LD 50 model based on nearest
neighbor approach; over the external validation set as shown in table 3.5. Since, the con-
sensus method including FP24 and fragments achieved the best performance in cross val-
idation, this feature was considered for further comparison. The method presented in this
chapter has outperformed both compared models. The overall sensitivity of developed pre-
diction method is almost double the performance achieved by the compared models on the
external validation set.
Performance measure in % FP24 and fragments TOPCAT T.E.S.T
Over all sensitivity 73.08 44.8 46.27
Sensitivity toxicity class 1 72.73 0.00 0.00
Sensitivity toxicity class 2 61.80 1.15 22.37
Sensitivity toxicity class 3 67.88 29.43 23.33
Specificity 94.62 88.96 89:25
Precision 73.50 41.98 45.61
Coverage 91.78 89.40 78.64
TABLE 3.5: Comparison of the prediction method with TOPKAT and T.E.S.T on the exter-
nal validation set .
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FIGURE 3.3: ProTox web-server Given the 2D coordinates of a compound, the web-
server calculates the toxicity prediction of the compound using the ensemble approach and
present the results with the predicted class, average similarity with the toxic compound in
the training set as well as percentage of prediction accuracy. Additionally, if any toxic frag-
ments are identified in the input compound, the fragment is reported with a confidence
score.
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FIGURE 3.4: ProTox web-server Given the 2D coordinates of a compound, the web-server
calculates the toxicity prediction of the compound and highlights the toxic fragments with
individual confidence score.
3.8 Discussion
The study reported in this chapter establishes a novel method for prediction of rodent oral
toxicity only available information on chemical data. Similarity method needs little informa-
tion to formulate a reasonable query; specifically it is not necessary to know about the ac-
tive confirmation of the query molecule as its based on the 2D coordinates of the molecules.
Similarity based model can be really useful when little or no information about the target is
known. Implementation of similarity method is computationally inexpensive and large data
sets can be predicted and analyzed in less time. A major limitation of this approach is that
prediction for each query (unknown) molecules depends largely depends on the activity and
diversity of the structurally similar molecules present in its training set which account to the
neighborhood behavior of the molecules. Though the molecules are compared using struc-
tural molecular fingerprints, however the scoring is based on the global similarity between
the compared molecules. Often it is observed that the property of a chemical compounds is
deeply connected with a local feature present in it. Hence, understanding of these local pat-
terns is extremely important in order to understand the activity of a molecule. In this study,
fragmentation approach was implemented inspired by the ’local feature based association’
hypothesis. It was observed in this study, that addition of fragments descriptor improved the
prediction for the most toxic classes such as class I by 5 % , class II by 9 % and class III by
3 % on cross-validation set as shown in table 3.3. Based on only individual fingerprints the
prediction method achieved highest performance with ECFP4, followed by a combination
of FP24 and fragments and only FP24 fingerprints individually has the least performance
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on cross-validation set. However, the best performance on external validation was achieved
by combination of FP24 and fragments. The ensemble method developed in this study was
compared with the commercial software TOPKAT and publicly available QSAR based method
T.E.S.T and has outperformed them in all evaluation measures on the external set as shown
in table 3.3 .
3.9 Conclusion
In this study, an ensemble model based on similarity and fragments approach was developed
to predict rodent oral toxicity of the chemicals by using concatenated ’FP24’ fingerprints and
statistically analyzed toxic fragments. The similarity approach is based on the neighborhood
behavior of chemical compound and representation of their structural features using molec-
ular fingerprints. In the fragment based approach, each molecular structure was compared
to statistically analyzed fragments by using substructure search that represents the presence
or absence of particular toxic substructures in the molecules with a confidence score. The
application of this ensemble approach has the potential to achieve a classification model
with high prediction accuracy as well as prediction confidence. The major advantage of this
approach is the capability to incorporate addition of new toxicity data easily and the model
can be extended to other toxic end points.
3.10 Application of the in silico prediction method in the develop-
ment of natural product database.
Natural products (NPs) plays an important role in the drug discovery pipeline. The constant
emergence of new natural product chemotypes with interesting structures and biological ac-
tivities leads to potential sub-librtary generation for target based screening. It has been ob-
served that many topological pharmacophore patterns are common between natural prod-
ucts and commercial drugs. Most recently, the novel prize 2015 in medicine was given for dis-
covery of natural products artemisnin and avermectin 46. This supports the fact that a better
understanding of the specific physicochemical and structural versatility of natural products
is important in the modern drug discovery development. Due to growing interest in natu-
ral products and its applications in the field of drug discovery, this was indeed important
to create a database of natural product which is publicly available. NPs are often associ-
ated with their complicated ring structures containing more than two rings often termed as
macrocycles (ring with more than 12 atoms). This is a special feature of NPs which help them
reorganize themselves structurally such that the important functional groups can strongly
interact with the target proteins. This is mainly done to reduce the entropic loss associated
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with the binding of ligands (NPs) with the proteins 47. Macrocyclic NPs like erythromycin,
rampamycin, tacrolimus have physicochemical properties like lipophilicity, metabolic sta-
bility, increased solubility and bioavailability 48 which make them desirable drug candidates.
Drugs like topotecan and irinitecan which has been approved for cancer therapy, has been
inspired from camptothecin isolated from the bark and stem of Camptotheca acuminata 49.
Camptothecin was initially found to inhibit the DNA enzyme topoisomerase I. However, due
to low solubility and high adverse drug reactions during clinical trails 50, it has to be modified
to its analogs topotecan and irinitecan.
At the same time, NPs are also known to be toxic and produce adverse effects on cellular or
system level. Alpha-amanitin, a well known toxic peptide produced by Amanita mushrooms
can lead to fatal liver and kidney disorders 51. Though the potentiality of NPs as drugs has no
doubt and well established in the area of drug design, however NPs are not excluded from the
curse of adverse drugs effects. Therefore, it is also important to study the toxicity profile of
NPs which is been considered as an therapeutic agent.
Even though there is a growing interest of NPs, there are only few NPs based database avail-
able for the scientific community. Most of the well-known NPs based database such as the
Dictionary of Natural Products 52 and Natural Product Alert (https://www.napralert.org/)
are either commercial or freely available only with restricted information. There was cer-
tainly a need of a NPs based database that is available freely to the scientific community,
containing information on various level like classification, toxicity class, mechanism of ac-
tion and pathways information. The knowledge based pool of Super Natural II database was
created keeping all the above mentioned factors. Super Natural II is the first publicly available
database of natural compounds consisting of 326,00 molecules.
The total number of compounds present in the Super Natural II database is 326,000. These
compounds were obtained from multiple data sources including; databases, literature re-
view, and expert knowledge as cited in the Super Natural II website . The Kyoto Encyclopaedia
of Genes and Genomes (KEGG) 53 is a popular metabolic database. This database is used to
generate the metabolic pathways for the natural compounds in the Super Natural II database.
Cross-references between resources are provided in the database either internally or exter-
nally via identifier mapping.
Some of the database sources which have been used in the creation of Super Natural II database
is listed below
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Source Number of compounds
Ambinter 48649
Analyticon Discovery 32641
Cyano Biotech GmbH 32
HMDB 4744
Indofine 572
InterBioScreen 84265
Iris 959
KEGG 2324
MedChemLabs 128
MetaCyc 350
Microsource 501
Molecular Diversity Preservation International 26639
Nubbe Natural Products 581
Princeton Biomolecular 27394
Selleckchem 178
Sigma 364
Specs 3498
TCM Database 23943
TimTec 70
UEFS Natural Products 117
Universal Natural Products Database 166097
3.10.1 Toxicity prediction
The toxicity related to NPs which are used as medicine is usually not well established. There
is a lack of standardized reporting system as well as limited interest in the toxicity profiles of
already known drugs from natural sources. In the year 2013, a study reported to the American
Association of Poison Control Centers, almost 38,955 natural product-related exposures were
reported 54,55. Most of the NPs are not always marketed in their pure form , but in combina-
tion with more than one NPs in mixture. This certainly adds to the complexity to identify
a cause and -effect relationship between an individual NPs and specific toxicity. Adverse
effects of NPs have been associated with nephrolithiasis, rhabdomyolysis, hepatorenal syn-
drome and many more 55. For instance, daily intake of creatine monohydrate has been asso-
ciated with acute folcal interstitial nephritis with tubular injury 56. On the other hand, some
toxic profiles of NPs are also important for killing tumorous or infectious cells, in case of NPs
with anticancer properties. It should be noted that some NPs are toxic in nature and hence,
there is a need to discriminate the non-toxic NPs and toxic NPs. The toxicity profiles of any
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compound is dependent on the dose and duration as well as physiological state of the sys-
tem administered; and have to be studied in details and cannot be generalized. Nevertheless,
having some first hand information of the toxicity profile based on its structural feature will
lead to be a preventive measure. The toxicity prediction is categorized into six major classes,
ranging from class I to class VI based on the lethal dose (LD 50) values in mg/kg body weight in
rodents. The toxicity prediction method involved in this section is based on ProTox 57.The to-
tal number of compounds for which toxicity information is available is 170000 compounds,
the unpredicted compounds were mostly due to out of prediction range of the method and
so reported as zero. All the NPs in the database has a link connected to Protox web-server 57,
which can address the toxicity prediction in details. As example of compounds with toxicity
class information in Super Naturall II database is shown in the figure 3.10.1
Toxicity class number of compounds
I 2392
II 10579
III 11969
IV 60821
V 59892
VI 20716
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FIGURE 3.5: Super Natural database Given the 2D coordinates of a compound, the calcu-
lates the toxicity prediction of the compound using the ensemble approach and present the
results with the predicted class, as well as properties of the molecule and further possibility
to search pathways.
3.10.2 Graphical user interface and information retrieval
In this section, the different search options available via Super Natural II database are de-
scribed. To help the user, a web-based search tool including a molecular structure sketcher
interface was designed. Users can also search the database using properties, toxicity class, or
by combination of criteria. Furthermore, the integrated PubChem 58 search for compound
name is implemented. For every search results the main properties and the chemical struc-
ture of the compound, as well as a link to download the structure file in the Mol2 format is
implemented.
Apart from toxicity prediction, some of the important search options are listed below:
1. Similarity search: To compare two compounds on the basis of their structural sim-
ilarity, a molecular fingerprint based similarity search was implemented using Open
Babel library. The two-dimensional similarity of the compound were given a Tani-
moto score. It compares the structural similarity between the query molecule and the
database entries using a concatenated fingerprint of the ’FP2’ and ’FP4’ Open Babel
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fingerprints. Pre-computed fingerprints for all database entries are stored as blob ob-
jects in the MySQL-database. For any input query structure it is calculated during the
search. The top 15 similar compounds are retrieved as result.
2. Mechanism of action: The elucidation of precise mechanism of action of NPs remains
a considerable challenge in drug discovery. Target identification and mechanism of
action can be obtained by direct biochemical essays, genetic interactions or computa-
tional inference. Information of mechanism of action of unknown compounds greatly
facilitates the use of such compounds as a starting point for investigation of funda-
mental biological processes. Some NPs and other compounds have already known
mechanism of action and target information. This information was used to predict
the mechanism of action of unknown NPs which share structural similarity with the
known compounds. The drug-target information for more than 195 000 pharmacolog-
ically known compounds were extracted from SuperTarget 59. These drugs were com-
pared with all the compounds present at the Super Natural database using structural
similarity score (Tanimoto coefficient) of 0.8 and above. These information were stored
in the database using an unique identifier. SuperPred web-server was used to predict
the targets for the natural product compounds, which has a prediction accuracy of 75.1
percent60.
3. Pathways: In this section, the information from KEGG pathway were mapped for the
natural compounds present in the Super Natural II database. The NPs were mapped to
potential targets with respect to their similarity to the reference drugs (as explained un-
der ’mechanism of action’ section), to display pathway maps. Taking an example for a
search considering ’Homo sapiens’ as species information and ’Apoptosis’ as pathway,
the information can be obtained as a pathway map with all known targets highlighted.
A curser-over on the target will display drugs action on the target. The number of drugs
is limited to 15 hits with a similar NPs and their related similarity score. The database
currently considers metabolic pathways of Homo sapiens, bacteria and fungi.
3.11 Availability
The method is made publicly assessable via a web-server called ’ProTox’ (Prediction of Ro-
dent Oral Toxicity (http:tox.charite.de ). It is the first freely available method based on
chemical similarity and the identification of toxic fragments for insilico prediction of rodent
oral toxicity. This method demonstrates good performance in comparison to available QSAR-
based methods.
The Super Natural II database is a freely available knowledge resource of natural compounds
with different embedded search options. The compounds present in database comprise of
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diverse chemotypes with a wide range of biological as well as pharmacological activities. Ad-
ditionally, toxicity profiles of the natural products are provided. Therefore, it is believed that
the database will be effective and beneficial in the studies involving metabolomics, virtual
screening and design of novel compounds. Since its publication, Super Natural database II
database has been used in many researches for novel discoveries 61,62 as well several analy-
sis purposes. Super Natural II database is available at (http://bioinf-applied.charite.
de/supernatural_new/index.php)
Chapter 4
Development of binary classifiers for
predictions of compounds active in
toxicological pathways
Several approved drugs are withdrawn from the market for safety reasons and there are many
reasons including metabolism and different mechanism that can cause toxicity 63 . The cur-
rent improvement in the field of predictive science related to toxicity prediction led to the
development of several computational methods. These methods uses the molecular descrip-
tors, biological data and chemical structures and analyze them using a statistical analysis;
represents them in a mathematical equation. These mathematical models describes the re-
lationship between the structures and activity and predicts the toxic effects 65. This kind of
approach is an unbiased way to asses the data to generate relationships and predict their
toxic outcomes. Such approaches has the capability to discover potentially new SARs (Struc-
ture Activity Relationships) and can lead to new ideas in assessment of mechanisms by which
chemical interact with biological systems. However, the results are highly dependent on the
quality of the chemical space used to build the model, so a careful validation is important for
the effective used of these approaches.
In this chapter, different in silico approaches used to predict the outcomes of the compounds
that have the potential to interact with the molecular targets active in toxicological pathways
are discussed. The data used in this study was obtained from the Tox21 Challenge platform
(http://www.epa.gov/chemical-research/toxicology-testing-21st-century-tox21)
provided by the National Institute of Health, USA (NIH). Tox21 challenge data was created us-
ing standard assays and experimental conditions and therefore serves as the ’gold standard’
data to asses and compare computational prediction methods.
34
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In the first section of this chapter, a similarity-based fingerprint approach is discussed, which
is inspired from the method explained in the previous chapter. This method was used to pre-
dict the activity of the compounds in the Tox21 challenge and has been ranked 8th out of 30
models, 9th out of 32 models and 9th out of 35 models for the targets SR-HSE (Heat shock
factor response element), ER-LBD (Estrogen receptor alpha) and NR-AhR (Aryl hydrocar-
bon receptor) respectively, submitted to the challenge (https://tripod.nih.gov/tox21/
challenge/leaderboard.jsp ).
In the second section, different machine learning models are discussed which were devel-
oped using the same Tox21 challenge data and their performance as compared to the top
models in the Tox21 challenge for the three targets. As well as their better performance com-
pared to the method similarity-based fingerprint approach described in the first section. Ad-
ditionally, taking example of one of the targets, an analysis of the active chemical space was
done to understand which machine learning models can correctly predict which chemotypes
with highest confidence scores.
4.1 Introduction
In the year 2008, the U.S National Institutes of Health (NIH) and the U.S environmental Pro-
tection Agency (EPA), later joined by the U.S Food and Drug Administration (FDA) came to-
gether to establish a platform for the future of toxicity testing. With the vision to transform
toxicology into predictive science, they came up with the initiative ’The U.S Toxicology in
the 21 st Century (Tox21)’ 64. The main objective of this initiative is to shift ’the traditional
experimental animal toxicology studies to one based on target-specific, mechanism-based, bi-
ological observations largely obtained using in vivo assays’ 43 . Through this consortium, a
platform ’the Tox21 Data Challenge’ was organized for computational toxicologists to develop
and validate their predictive models. The consortium screened a large library of compounds,
including chemicals and drugs involved in different pathways and responsible for eliciting
toxic effects.
4.2 Targets / Assays
In this study targets from two different pathways namely: nuclear receptor signaling path-
ways (AhR and ER-LBD) and stress response pathways (HSE) are considered. The toxicity
profiles of these targets are well established and are taken from the U.S Tox21 program.
The Aryl hydrocarbon receptor (AhR) is a ligand activated transcription factor, involved in
the regulation of biological responses to planar aromatic (aryl) hydrocarbons. Side effects
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associated with this target results in a adaptive responses to environmental changes by in-
duction of metabolising enzymes (CYP 1A 1 and CYP 1B1), producing toxic metabolites. It is
also known to interact with other nuclear receptors 65 .
Estrogen Receptor (ER) is a nuclear hormone receptor which plays an important role in metabolic
homoeostasis and reproduction. ER is responsible for the regulation of genes involved in
growth and development of various tissues. Many chemicals like diethystilbestrol, bisphenol
A are known to binds to ER- receptor and inhibits growth. Tamoxifen is a drug which is in-
volved in fatty liver disease as well as liver toxicity is known to bind to ER receptor and inhibit
the gene transcription process 65 .
Many chemicals under environmental and physiological stress state may activate heat shock
/unfolded protein response. Therefore Tox21 program developed a HSE-bla Hella cells based
assays to identify compounds that are active in HSR signalling pathway 65 .
4.3 Data preparation and processing
The publicly available Tox21 data challenge 2014 10k library was taken from the Tox21 chal-
lenge website containing the 2D structure of the molecules. The standardization of the chem-
ical structures was done using the Instant Jchem software (version 6.2 , ChemAxon). The
standardization protocol includes the following step:
1. Removal of water molecules.
2. Aromatization of all the structures.
3. Transformation of adjacent positive and negative charges into double or negative bonds,
wherever applicable.
4. Removal of explicit hydrogen.
InChIKeys for the molecules were calculated using RDKit nodes in KNIME; this was done
to keep an account of the duplicate structures and filter them. In case identical molecules
for a given target had two different activities value (i,e one being active and other inactive),
they were marked ambiguous and removed from the training set. After the standardization
protocol and duplicate removal, the final training set and external validation set had similar
class distribution as shown in tables 4.1 and 4.2 .
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Target Total actives inactives Ratio (actives/inactives)
AhR 6901 769 6132 0.125
ER-LBD 6801 346 6455 0.053
HSE 7328 308 7019 0.043
TABLE 4.1: Training set class distribution. The table shows the total number of compounds
as well as number of actives and inactives compounds for each target.
Target Total actives inactives Ratio (actives/inactives)
AhR 610 73 537 0.135
ER-LBD 600 20 580 0.034
HSE 610 23 588 0.039
TABLE 4.2: External test set class distribution. The table shows the total number of com-
pounds as well as number of actives and inactives compounds for each target.
4.4 Molecular fingerprints
Four different fingerprints were used in this prediction method.
4.4.1 Substructure fingerprints
Substructure fingerprints are based on structural keys which were primarily designed for
high speed screening of chemical databases. The structural keys are commonly represented
as a boolean array or bitmaps, in which each bit represents presence or absence of a spe-
cific structural feature. These patterns include the elements, important electronic config-
uration (such as ‘sp3 or triple-bond nitrogen), common functional groups (such as alco-
hols, amines, hydrocarbons), ring systems (such as cyclohexane, pyridine or naphthalene),
functional group of special importance (such as organo-metallic group or drugs like steroids
based structures ). The public Molecular ACCess System (MACCS) structural keys are 166 pre-
defined substructures defined as SMARTS based on dictionary-based class of fingerprints 66 .
These fingerprints were created using the RDKit and CDK nodes in KNIME.
4.4.2 Circular fingerprints
This fingerprint was explained in the section 3.3.2
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4.4.3 Estate fingerprints
The Estate fingerprint is based on the the concept of Electrotopological State Indices for atom
types generated from a combination of electronic, topological and valence state information
of an atom as described by Hall and Kier 67. The fingerprint contains 79 bits using the E-state
based concept fragments. These fingerprints were created using the cdk node in KNIME .
4.4.4 Toxicity fingerprints
Toxicity based fingerprint ‘ToxPrint’ used in this study includes a public set of chemotypes
encoding the generic geno-carcinogenic substructures (https://toxprint.org/).
FIGURE 4.1: Concatenated fingerprint A combination of sub structural fingerprint
(MACCS), toxic alerts based fingerprint (ToxPrint), circular fingerprint (ECFP4) and
property-based binary fingerprint 64
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Fingerprints Designed descriptors Encoding Length
MAACS structural fragments one to one matching of
bits position and frag-
ments keys
166 or 960 bits
ECFP extended graph connec-
tivity
mapping of hash func-
tion to virtual feature
space
infinite
FP2 or FP4 paths or subgraph mapping of hash func-
tion to fixed length
user-defined (1024
or 2024 bits)
Estate valence state informa-
tion of atom
mapping of hash func-
tion to fixed length
fixed length
ToxPrint substructures one to one matching of
bits position and sub-
structure keys
fixed length
TABLE 4.3: Types of fingerprints and their encoding description. Five different fingerprints
used in this study and their respective encoding parameters.
4.5 Molecular descriptors
Molecular descriptors encoding the physico-chemical properties of the molecules for the
data set were calculated using the the RDKit descriptor calculation node in KNIME 68. A total
of 43 descriptors were calculated and their individual scores were normalized using Z-score
normalization. The descriptors with missing values were removed. Additionally, by plotting
the ‘principal components’, descriptors with low variance to both active and inactive class
were removed. Finally, 13 descriptors were selected and used in this study as presented in the
table 4.4 . The SlogP descriptors account for the hydrophobic and hydrophilic effect 69. Chi
indexes takes into consideration of valence value to encode sigma, pi and lone pair interac-
tion70. Kappa shape descriptors compares the molecule with extreme shape for the number
of atoms 70, the applications of Kappa shape descriptors in the field of in silico predictions
has been extrusive 69 .
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Descriptor name Description
SlogP Log of the octanol/water partition coefficient
Chi0v Atomic valence connectivity index (order 0)
Chi1v Atomic valence connectivity index (order 1)
Chi2v Atomic valence connectivity index (order 2)
Chi3v Atomic valence connectivity index (order 3)
Chi4v Atomic valence connectivity index (order 4)
Chi1n Simple molecular connectivity index for path (order 1)
Chi2n Simple molecular connectivity index for path (order 2)
Chi3n Simple molecular connectivity index for path (order 3)
Chi4n Simple molecular connectivity index for path (order 4)
kappa1 Kappa index for 1 bonded fragment
kappa2 Kappa index for 2 bonded fragment
kappa3 Kappa index for 3 bonded fragment
TABLE 4.4: Molecular descriptors used in the method in combination with fingerprints .
4.6 Methods
In this section, different methods developed for prediction of the binary classes of Tox21 data
are described. Firstly, a similarity based approach in combination with Naive Bayes finger-
prints learner is reported, followed by different machine learning algorithms such as Naive
Bayes (NB), Random Forest (RF) and Probabilistic Neural Network (PNN).
All the methods takes 2d structure of chemical compounds as input and predicts the out-
comes with confidence score for the compound to be active or inactive for the given target.
4.6.1 Similarity-based fingerprint method
Similarity based method is based on the similar strategy as explained in the section 3.4.1.
Additionally, three Tanimoto coefficients (Tc) were computed, the maximum Tc to actives in
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the training set (T1), the average Tc to actives in the training set (T2), and the maximum Tc
to all inactives in the training set (T3).
The Naive Bayes fingerprint learner is a variant of a Naive Bayes for fingerprints columns.
This is not a model based on Naive Bayes algorithm, however this variant implements the
Naive Bayes like algorithm that incorporates sparsely occupied bits and unbalance class dis-
tributions
The consensus score from both the method was considered after normalization of all the
scores using Z-score normalization followed by a Gaussian distribution and normalization
implemented in KNIME. The scores were obtained in a range of 0 to 1. The combination of
each scores were considered and ranked and the highest scores were considered as the best
score 64 .
FIGURE 4.2: Workflow of the similarity-based fingerprint method Schematic representa-
tion of the similarity based method models used to predict the outcomes of Tox21 data
4.6.2 Naive Bayes
The Naive Bayes classifier is based on the assumption of the Bayesian theorem of conditional
probability 71 . In order to classify data point, NB assumes an independence of features and
calculates the overall probability for each class. In the study, NB estimates the probability
for a given chemical structure to be active based on the presence or absence of structural
features for a given target. Based on these individuals features, NB classifies a compound
as active if the probability for being active exceeds the probability for being non-active. NB
classifier was implemented using the Naive Bayes Learner and Predictor nodes in KNIME 71 .
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The Learner node takes the training data as well as the features and parameters for the model.
The maximum number of unique nominal values per attribute was set to 20. The predictor
node takes the model and test data and as output classifies the test data with an individual
class and score 71.
The model was trained using different molecular fingerprints and molecular descriptors to
obtained the optimal prediction parameters.
4.6.3 Random Forest
Random Forest classification which is based on decision trees was developed by Breiman 72.
In this classifier each tree is independently constructed and each node is split using the best
among the subset of predictors randomly chosen as node. That is, RF is capable of describing
the relationship between independent features such as fingerprints, molecular descriptors
with dependent variables such as activity and toxicity. The RF grows collection of trees often
termed as forest, and uses these trees for classifying a data point into one of the classes. The
type of randomness used in our model to make the the classification trees grown in the forest
are dissimilar and uncorrelated from each other and is based on random selection of input
variables. The split criterion Gini which has been accepted as best choice previously 73 was
chosen and obtained best performance for the target AhR. However, for ER-LBD and HSE,
information gain ratio as split criterion gave best results. The number of trees in the forest
was limited to 1000 and a data sample of ratio of (80:20) for AhR and (70:30) for ER-LBD and
HSE was chosen with replacement for each tree, this step is similar to bootstrapping. This
was done to achieve low error rate of convergence. Furthermore, a square root function was
used for attribute sampling and different sets of attributes were chosen for all the trees. The
predictor node predicts the class for each compound in the test data based by the majority
vote classification trees in the forest, each compound has an overall prediction score and
individual class confidences. This model was implemented using the Tree Ensemble Learner
and Predictor nodes in KNIME.
4.6.4 Probabilistic Neural Network
The Probabilistic Neural Network is based on a statistical algorithm ‘Kernel discriminant
analysis’ 74 . PNN is a four layer, feed-forward neural network that is widely used in the area
of pattern recognition, nonlinear mapping and estimation of probability of class member-
ship and likelihood ratios 75. The first layer which is also the input layer consists of sets of
measurements. The pattern layer which is the second layer consists of the Gaussian function
uses the given set of data points as centers. The summation layers or the third layer performs
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an average operation of the outputs from the second layer for each class. The fourth layer
that is the output layer predicts the class based on votes from the largest values 76. Similarly,
like NB and RF, PNN was also implemented using KNIME. The PNN learner node takes the
numerical data as input and PNN predictor node predicts the test data with a confidence
score and class. In this model, all the parameters value were kept as default except for that
the maximum number of Epochs was set to 42 to reduce the computational time complexity.
4.7 Constructions of the machine learning models
The Tox21 dataset for the respective targets was separated into 80 % training set and 20 %
internal test set. A stratified sampling based random partitioning was done in order to keep
the similar class distribution in both the sets. This was done to tune the model parameters
and to avoid any random prediction.The data set used to train the model was highly imbal-
anced having active class (minority) and inactive class (majority). Due to lack of feasibility to
obtain more data for the minority class in case of most targets, a stratified random sampling
was applied to handle the classification accuracy error due to imbalanced data. Addition-
ally, a set of 647 chemical structures was considered as external validation set. In order to
optimize the best descriptors for individual models, four different fingerprints and rationally
selected physico-chemical properties based molecular descriptors were chosen to represent
the chemical structures. Using these descriptors individually and in combination, three dif-
ferent machine learning models were developed.
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FIGURE 4.3: Workflow of the machine learning methods Schematic representation of three
different algorithms developed for the predictions of active compounds in three different
target classes respectively
4.8 Performance evaluation
In this study to evaluate the models performance, the area under the receiver operating char-
acteristic (ROC) curve, also known as AUC was considered along with balance accuracy. ROC
curve plots the true positive rate against the false positive rate and is traditionally used for
binary classifiers 77. A perfect model is believed to have AUC of 1 and a random model will
have a value of 0.5.
ROC − cur ve = Sensi t i vi t y
1−Speci f i ci t y
Additionally, in order to avoid inflated performance estimates on the imbalanced data bal-
anced accuracy as another performance measure was considered. Balanced accuracy is de-
fined as the arithmetic mean of sensitivity and specificity 78.
B al anced −accur ac y = Sensi t i vi t y +Speci f i ci t y
2
The models were validated based on two validation approaches, 13-fold cross-validation and
independent external validation. For 13-fold cross-validation the data set was split into 13
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roughly equal-sized parts, and then the model was fit into 12 parts of the data and the error
rate was calculated in the other part. The process is repeated 13 times so that each of the part
can be predicted as the validation set.
AUC and the cross-validation protocol was implemented in KNIME using the ROC curve
node and cross-validation meta node respectively.
4.9 Results
In this section the results of the different prediction algorithms are explained in detail. In
case of similarity based-fingerprint method, concatenated fingerprint was implemented and
for the machine learning methods four different fingerprints ECFP4, MAACS, ToxPrint and
Estate fingerprints in combination with different molecular descriptors were used. In this
study it was observed that all the classifiers achieved almost prediction accuracies of 80 %
and above. Due to the imbalanced data set, accuracy cannot reflect the performance of the
models. The models were additionally evaluated on the ROC-AUCs which is more accurate
performance quality criterion for the models. Based on the results obtained from 13-fold
cross-validation and external validation, RF based models achieved the best performance
for all the three targets followed by NB and PNN.
For all the targets it was observed that RF model with MACCS fingerprints as feature exhibit
the best performance. Only in case of AhR, ToxPrint fingerprints also performed equally well
with an AUC value of 0.89 and 0.88 for the external validation and cross-validation respec-
tively (see tables 4.9 and 4.10) which is comparable to the performance of the similarity-
based fingerprint method. The total number of actives as well as molecules for AhR target was
relatively large as compared to ER-LBD and HSE; this confirms that the size of the training set
as well as the ratio between active and inactive molecules is an important factor contributing
to its superior performance for AhR (see tables 4.1 and 4.2 ).
In the following sections a comparison of different molecular fingerprints and thei combina-
tion with the molecular property based descriptors for different models on cross validation
as well as external validation set are provided in details.
4.9.1 Results: Similarity-based fingerprint method
In this method all the models based on individual fingerprints (ECFP4, MACCS and ToxPrint)
showed good performance with an AUC mostly above 0.75. However, the best performance
was achieved by a concatenation of all three fingerprints with a property-based-fingerprint
encoding the topology of the molecules. This method was used in the Tox21 challenge to
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submit results. The best results were achieved in the Tox21 challenge using this method is for
the target ER-LBD 64 .
Method Descriptors NR-AhR ER-LBD HSE
Similarity based fingerprint concatenated fingerprints 0.90 0.86 0.80
TABLE 4.5: Cross validation results for Similarity based prediction. Area under the curve
(AUC) from receiver-operating characteristics (ROC) analysis
Method Descriptors NR-AhR ER-LBD HSE
Similarity based fingerprint concatenated fingerprints 0.89 0.79 0.85
TABLE 4.6: External validation results for Similarity based prediction. Area under the
curve (AUC) from receiver-operating characteristics (ROC) analysis
4.9.2 Results: Naive Bayes
In case of NB classifier, MACCS fingerprints in combination with molecular property based
descriptor and ToxPrint fingerprints performed comparatively better for AhR with AUC val-
ues of 0.82 and 0.83 (cross-validation) and 0.84 and 0.82 (external validation) respectively as
shown in the tables 4.7 and 4.8. On the other hand, the performance for the targets ER-LBD
and HSE were poor with an AUC value below 0.75 both in cross-validation and external vali-
dation.
Method Descriptors NR-AhR ER-LBD HSE
NB MACCS 0.83 0.73 0.67
NB MACCS + descriptors 0.82 0.73 0.63
NB EState 0.81 0.73 0.71
NB EState + descriptors 0.79 0.77 0.69
NB ECFP4 0.77 0.76 0.70
NB ECFP4 + descriptors 0.78 0.77 0.69
NB ToxPrint 0.83 0.71 0.68
NB ToxPrint + descriptors 0.80 0.72 0.70
TABLE 4.7: Cross validation results for Naive Bayes model. Area under the curve (AUC)
from receiver-operating characteristics (ROC) analysis
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Method Descriptors NR-AhR ER-LBD HSE
NB MACCS 0.82 0.69 0.79
NB MACCS + descriptors 0.84 0.70 0.77
NB EState 0.79 0.67 0.72
NB EState + descriptors 0.78 0.67 0.60
NB ECFP4 0.77 0.71 0.76
NB ECFP4 + descriptors 0.78 0.71 0.74
NB ToxPrint 0.82 0.63 0.63
NB ToxPrint + descriptors 0.83 0.60 0.60
TABLE 4.8: External validation results for Naive Bayes model. Area under the curve (AUC)
from receiver-operating characteristics (ROC) analysis
4.9.3 Results: Random Forest
RF classifier for the target AhR showed a good performance with MACCS, ECFP4 and Tox-
Print fingerprints with an AUC values above 0.88 on the 13-fold cross-validation as well as
on the external validation. The highest AUC scores of 0.90 and 0.91 (cross validation) and
0.90 and 0.87 ( external validation) were achieved with MACCS fingerprint individually and
MACCS fingerprints in combination with molecular property based descriptors, respectively.
The combination of descriptors did not improve the AUC value of the eternal set in this case.
Similarly, MACCS fingerprints based RF model achieved highest performance for ER-LBD
and HSE with AUC values of 0.83 and 0.80 (cross-validation) and 0.81 and 0.86 (external vali-
dation) respectively as shown in the tables 4.9 and 4.10 .
Method Descriptors NR-AhR ER-LBD HSE
RF MACCS 0.90 0.83 0.78
RF MACCS + descriptors 0.91 0.86 0.80
RF EState 0.77 0.59 0.66
RF EState + descriptors 0.79 0.55 0.67
RF ECFP4 0.87 0.82 0.77
RF ECFP4 + descriptors 0.89 0.80 0.78
RF ToxPrint 0.88 0.80 0.78
RF ToxPrint + descriptors 0.88 0.85 0.80
TABLE 4.9: Cross validation results for Random Forest model. Area under the curve (AUC)
from receiver-operating characteristics (ROC) analysis
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Method Descriptors NR-AhR ER-LBD HSE
RF MACCS 0.90 0.81 0.86
RF MACCS + descriptors 0.87 0.77 0.81
RF EState 0.78 0.51 0.87
RF EState + descriptors 0.76 0.74 0.73
RF ECFP4 0.87 0.78 0.81
RF ECFP4 + descriptors 0.88 0.78 0.83
RF ToxPrint 0.89 0.71 0.70
RF ToxPrint + descriptors 0.74 0.62 0.69
TABLE 4.10: External validation results for Random Forest model. Area under the curve
(AUC) from receiver-operating characteristics (ROC) analysis
4.9.4 Results: Probabilistic Neural Network
PNN based classifier classifier performed comparatively better for AhR with an AUC score of
0.84 (cross-validation) and 0.85 (external validation) with ECFP4 as the best feature. However,
the performance for the targets ER-LBD and HSE was relatively poor and all the AUC values
were mostly less than 0.80 for both cross-validation and external validation as shown in tables
4.11 and 4.12 .
Method Descriptors NR-AhR ER-LBD HSE
PNN MACCS 0.90 0.83 0.78
PNN MACCS + descriptors 0.91 0.86 0.80
PNN EState 0.77 0.59 0.66
PNN EState + descriptors 0.79 0.55 0.67
PNN ECFP4 0.87 0.82 0.77
PNN ECFP4 + descriptors 0.89 0.80 0.78
PNN ToxPrint 0.88 0.80 0.78
PNN ToxPrint + descriptors 0.88 0.85 0.80
TABLE 4.11: Cross validation results for Probablistic Neural Network model. Area under
the curve (AUC) from receiver-operating characteristics (ROC) analysis
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Method Descriptors NR-AhR ER-LBD HSE
PNN MACCS 0.81 0.69 0.77
PNN MACCS + descriptors 0.82 0.76 0.72
PNN EState 0.78 0.68 0.76
PNN EState + descriptors 0.84 0.77 0.53
PNN ECFP4 0.85 0.69 0.70
PNN ECFP4 + descriptors 0.82 0.75 0.67
PNN ToxPrint 0.82 0.69 0.67
PNN ToxPrint + descriptors 0.83 0.74 0.60
TABLE 4.12: External validation results for Probablistic Neural Network. Area under the
curve (AUC) from receiver-operating characteristics (ROC) analysis
4.10 Analysis of chemical space
The patterns associated with active chemical structures were evaluated by analyzing the com-
pounds which were correctly and incorrectly predicted by respective machine learning mod-
els. The target ER-LBD was chosen mainly because the ensemble method achieved the best
performance for this target 64. It is of particularly interesting to investigate which chemical
space was correctly or wrongly represented by different molecular fingerprints (ECFP4 and
MACCS). All the active chemical structures predicted by the RF model were also correctly
predicted by the NB model as illustrated in figure 4.4. Additionally, the NB model predicted
five more active compounds correctly whereas the PNN model failed to predict a single ac-
tive compound. On the other hand, the number of inactive compounds incorrectly predicted
(false positives) in NB models was the highest with 80 incorrect predictions, followed by RF
with 4. PNN based models predicted all the inactives correctly supporting the fact that it is
biased towards majority class coverage as reported in table 4.16. Additionally, it is observed
that NB based model with both ECFP4 and MACCS fingerprints predicted the active com-
pounds with highest confidence scores compared to RF models as reported in table 4.13. It
could be because RF fails to predict the active class when the molecules become more com-
plex irrespective of the fingerprints considered as shown in figure 4.4.
Chapter 4. Binary classifiers for in silico toxicity prediction 50
FIGURE 4.4: Chemical space analysis The above figure shows the different actives present
in the external set of ER-LBD. The compounds highlighted in pink boxes and blue boxes
were correctly predicted by Random Forest classifier and Naïve Bayes classifiers respectively.
Additionally, respective confidence scores for each classifier are shown.
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Molecule id NB with MACCS RF with MACCS NB with ECFP4 RF with ECFP4
NCGC00261424-01 0.99 0.58 1 0.77
NCGC00261052-01 0.57 0.07 0.02 0.12
NCGC00357055-01 0.95 0.01 0.01 0.06
NCGC00357018-01 0.99 0.94 1 0.94
NCGC00357052-01 0.99 0.04 0.99 0.16
NCGC00357021-01 0.99 0.68 0.99 0.31
NCGC00356994-01 0.99 0.52 0.99 0.36
NCGC00357111-01 0.99 0.06 1 0.15
NCGC00261828-01 0.13 0.05 1 0.20
NCGC00261342-01 0.01 0.02 0.99 0.08
NCGC00357230-01 0.04 0.05 0.98 0.02
TABLE 4.13: ER-LBD active compounds correctly predicted in External set using RF and
NB models using MACCS and ECFP4 fingerprints. alone with confidence scores. Color
denotes different molecules illustrated in the figure 4.4
4.11 Comparison with Tox21 challenge top performers
After the Tox21 data challenge winners were announced, a comparison of the top performing
models as well as the similarity-based fingerprint method with the machine learning models
were carried out. The best prediction achieved in this study is by RF classifier with MACCS
fingerprints .
In the Tox21 data challenge, the winning method for the targets NR-AhR and SR-HSE was
achieved by Mayr et.al 79. The models were developed based on deep learning algorithm
which comprises of abundance of deep neural network. The descriptors used in this method
is a combinations of ECFP fingerprints, physico-chemical descriptors and substructures pre-
viously used as toxic alerts.
For ER-LBD, the best method in the Tox21 data challenge was reported by Uesawa Y 80. The
model is based on the ensemble of 200 RF models and around 4,071 dragon as well as MOE
descriptors were used for the construction of the model.
When compared the RF model reported in this thesis performed equally good as the the
Tox21 top models in terms of AUC values as shown in table 4.14 . When the balanced accura-
cies were compared, the RF model outperformed all the top models in the Tox21 challenge as
shown in the table 4.15. When compared to the first model reported in this study (similarity-
based fingerprint), the Random Forest model in the study shows better performance with
respect to the AUC and balanced accuracy values.
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Method NR-AhR ER-LBD HSE
Similarity-based fingerprint 0.89 0.79 0.85
Random Forest 0.90 0.81 0.86
Tox 21 top models 0.92 0.82 0.86
TABLE 4.14: External validation result comparison with Tox21 Challenge winners. Area
under the curve (AUC) from receiver-operating characteristics (ROC) analysis
Method NR-AhR ER-LBD HSE
Similarity-based fingerprint 0.73 0.79 0.80
Random Forest 0.85 0.78 0. 82
Tox 21 top models 0.75 0.55 0.73
TABLE 4.15: External validation result comparison with Tox21 Challenge winners. Bal-
anced accuracies of the different models and targets
4.12 Discussion
In this study, two different methods were proposed for the prediction of interference of the
Tox21 challenge data set consisting of chemical compounds tested in two major biological
pathways; nuclear receptor pathway and stress response pathway. The data was generated
in a standard uniform experimental setup which serves as a gold standard data source for
evaluating performance of different prediction methods. In the first section, a similarity-
based fingerprint method was reported which is based on the ’ similarity property principle’
and concatenated fingerprints with molecular descriptors based binary fingerprints. This
method performed relatively better in combination of different fingerprints and descriptors.
In the second section, machine learning based models were developed in combination of in-
dividual fingerprints and as well as in combination with molecular property based descrip-
tors.
It was observed that the machine learning models based on RF classifier achieved best per-
formance when compared to other two machine learning models (NB and PNN) as well as
the similar-based fingerprint method. The superior performance of the RF models can be
attributed to the different tunning parameters chosen for individual targets (i,e RF algorithm
is robust to different tuning parameters). On the other hand, the poor performance of the
PNN model can be explained by its strong inclination towards the majority class coverage
of the training set. To understand this behavior in detail, the results were analyzed and it
is observed that PNN models were able to correctly predict all the true negatives in the ex-
ternal validation with a confidence score higher than 0.9 but failed to correctly predict the
actives (true positives) for all the three targets. On the other hand, NB models could predict
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the highest number of true positives with confidence scores higher than 0.99 in comparison
to the RF and PNN based models. However, NB lacks the prediction ability when it comes
to true negatives (inactives /majority class). Taking an example of a result from randomly
selected target ER-LBD, this trend was analyzed in details for each models considering two
different fingerprints (MACCS; ECFP4) as shown in table 4.16. RF based models are able to
identify the patterns associated with respective classes in case of imbalanced data set.
Furthermore, it is toxicity alert encoded fingerprints (ToxPrint) as well as atom state based
fingerprints (EState) that failed to obtain consistent performance across most of the targets
for various models. This could be due to the fact that the chemotypes in the training set do
not match with the pre-defined toxicity alerts encoded in the ToxPrint fingerprints. On the
other hand the MACCS fingerprints encodes the similar substructures like the one present
in the chemical space of the Tox21 challenge data and therefore performed better and con-
sistent across various machine learning models. This supports the fact that prediction of
toxicity can not always be encountered using a global approach (i,e identification of pres-
ence of certain toxic alerts in the chemical space). Target specificity and local substructures
closely associated with the chemical space addressed in the study play an important role in
the prediction process. In addition, selection of optimal descriptors which could represent
the chemical space and an unbiased classifier which can learn the patterns and used this
knowledge to predict activity of an unknown compound is in real a true essence of predictive
science.
Overall, in this study, it can be emphasized that a simple RF based classifier consistently
demonstrated robust prediction for all the three targets. This method is relatively simpler
and computationally less expensive than other methods of the Tox21 challenge. The results
of this study are equally good when compared with the Tox21 challenge top models with
respect to AUC values and are better with respect to balance accuracies. This further adds to
the usability of the optimal method developed in this study.
ER-LBD
True positives
(out of 20)
True negatives
(out of 580)
Cross validation
AUC
External validation
AUC
NB with ECFP4 9 500 0.76 0.71
NB with MACCS 8 468 0.73 0.69
RF with ECFP4 2 574 0.82 0.78
RF with MACCS 4 576 0.83 0.81
PNN with ECFP4 0 580 0.77 0.69
PNN with MACCS 0 580 0.78 0.69
s
TABLE 4.16: Classifications of actives and inactives in external set by different models for
ER-LB.
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4.13 Conclusion
In this study, different computational approaches were developed and compared to predict
activity of the chemical compounds. The random forest based in silico toxicity prediction
method is reported as the best method, emphasizing the importance of predictive toxicology
as a fast and reliable way to predict the toxic outcome of chemical compounds. Different
methods including the similarity-based as well as machine learning models were evaluated
using four different types of fingerprints and property based descriptors on Tox21 challenge
data. The results from this study suggest that RF based machine learning models can improve
the accuracies of prediction for all the three targets. The models developed in this study were
consistent with the top performing models in the Tox21 data challenge in terms of AUC and
have outperformed in terms of balanced accuracies. The model and results of this study will
be a great importance in the field of in silico toxicity prediction as well as for food and drug
regulatory agencies in development of decision-making tools to further improve their con-
trol over potentially toxic chemical compounds. Additionally, it can be concluded from the
result of this study that the combination and application of RF algorithm and substructure
based molecular fingerprints (MACCS) can be regarded as a very promising prediction tool
for evaluation of toxic effects of new chemicals.
4.14 Availability
Both the similarity-based fingerprint method and Machine learning methods are developed
using open source platform KNIME. The similarity based method is made available as KNIME
work flow to be used by the scientific community (http://tox.charite.de/tox/index.
php?site=links) . The machine learning methods will be made available via publication
(once accepted).
Chapter 5
A novel method to predict fatty liver
drugs using metabolic network based
target identification
Hepatocytes exhibits a wide range of functions extending from removal of toxic substances,
homeostatic regulations and synthesis of most plasma membrane constituents as well as
production of bile and hormones 81,82. Hepatocytes have higher metabolic activity in hu-
man and plays an important role in human metabolism. Alterations in the metabolism of
hepatic cells can lead to complicated liver problems like hepatitis, non alcoholic fatty liver
disease (NAFLD), cirrhosis and liver cancer, and can be serious threats to public health 81.
NAFLD is considered as the hepatic manifestation of obesity and metabolic syndrome as a
result of series of pathological changes, which ranges from reversible fatty liver (Steotosis) to
non alcoholic steatohepatitis (NASH) 81.
In this chapter,the molecular targets which plays important role in the metabolic network are
considered and further studied to detect drugs that have the potentiality to cause fatty liver
syndrome. Two different hypotheses have been postulated, based on that two different com-
putational prediction methods have been developed, ligand-based pharmacophore model
and molecular docking based prediction.
5.1 Introduction
In recent years, the most common cause of chronic liver disease in USA is contributed by
NAFLD. A recent study shows the need and cost associated with medication related to liver
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diseases as well as organ transplantation 83. Increase rates of obesity diabetes and high choles-
terol have results in growing concern for liver diseases 84. NAFLD and Steatohepatitis are well
linked but rare forms of drugs induced liver injury 85. In addition, fatty liver is often chronic
than acute even when drug induced 86. Even though it is well known that the lipid accu-
mulation in the liver is a starting point of the NAFLD; the underlying mechanism leading
to steotosis is still elusive 81. The adverse outcome of this pathology may be possibly pre-
vented once the molecular mechanisms involved in the metabolism of liver are unraveled.
On the other hand, this requires understanding of the coordinated behavior of a very large
number of interconnected network of drugs, molecular target as well as off-target, pathways,
metabolic network and metabolites.
Recent developments in the field of computational systems biology made it possible to pre-
dict the functional effects of systems perturbations using large scale network models. Subse-
quently, advances in the field of structural bioinformatics and chem-informatics have led to
the prediction of protein-drug off-target effects based on their ligand structures and binding
site information. Integration of these expertise provides a platform for evaluating metabolic
drug response in silico. The combination of these approaches was applied to investigate the
drugs that can cause fatty liver disease in human. Currently, there is no efficient treatment or
explanation involved in the mechanism of NAFLD.
This study represents a novel integration of the trio ’computational systems biology, struc-
tural bioinformatics and cheminformatics’ approaches to predict drugs involved in metabolic
syndrome and to understand the possible underlying mechanism.
5.2 Metabolic Network
The primary goal of cellular metabolism is the conversion of small molecules by intracellu-
lar catalysts (enzymes) to provide life maintaining support like growth and reproduction 87.
Enzymes can speed up certain biochemical reactions such as conversion of substrates into
product often by attaching chemical group or breaking off chemical group from the sub-
strates. Metabolic network can be termed as a simplified representation of this complex net-
work of biochemical reactions. The aim of the metabolic network is to unravel the basic
principles, predict cellular responses or to identify important metabolic targets for interven-
tion88,89.
Kinetic modeling is special kind of metabolic network representation 90,91. Kinetic models
represents metabolic network by a stoichiometric matrix Sij connecting metabolites Mi and
reactions vj. The time dependent changes in metabolite concentrations
[
Mi
]
are given by
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The reaction rates vj are dependent on external and internal parameters. Regulatory prin-
ciples considers compromise kinetic regulation through substrate availability as well as al-
losteric regulation. Additionally changes in enzymes structures or in abundance is also taken
into account. In a given cellular compartment, local enzyme and metabolite concentrations
are replaced by mean concentrations and it is assumed that stochastic variations can be ig-
nored. Given the rate of equations for the vj are constant, only additional parameters like ex-
ternal medium compositions such as metabolite, ion or hormone concentration are required
for the model.
Such model can be applied to calculate the concentration of metabolites and the rates of
their mutual chemical interconversion in response to varying external conditions like nu-
trient supply and varying internal conditions like enzymes availability and demand. These
calculations are further utilized to quantify complex cellular functions as cellular growths,
detoxification of drugs and xenobiotic compounds or synthesis of exported molecules 87.
The kinetic model used in this study includes the main pathways of carbohydrate, amino acid
and fatty acid metabolism comprising: glycolysis, fructose metabolism, galactose metabolism,
gluconeogenesis, glycogen metabolism, citric acid cycle, fatty acid synthesis, cholesterol syn-
thesis, beta-oxidation, respiratory chain, oxidative phosphorylation, mitochondrial electro-
physiology, malate-aspartate shuttle, glycerol-3-phosphate shuttle, urea cycle, glutamine syn-
thesis, glutaminolysis, serine metabolism, alanine metabolism, triacylglycerol synthesis, lipid
storage and mobilization, VLDL assembly and secretion, as well as ketone body production.
The model describes the exchange of the plasma metabolites glucose, galactose, fructose,
pyruvate, lactate, glycerol, acetate, beta-hydroxybuterate, free fatty acids, ethanol, acetoac-
etate, oxygen, glutamine, glutamate, serine, alanine, ammonia as well as the storage of glyco-
gen and triglycerides. The metabolic system takes kinetic effects on inter convertible en-
zymes in response to the hormones insulin and glycogen into account.
5.3 Selection of target
The above kinetic model based on the central hepatic metabolism was used to identify en-
zymes which upon inhibition lead to an increased fat accumulation within the hepatocytes.
The systematic inhibition of each enzymes by 10 % and monitoring of the resulting triglyc-
eride content in a healthy hepatocyte under physiological conditions revealed the top ranked
enzymes and the corresponding pathways as shown in the table 5.1 .
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Enzyme Functioning pathways
apoB synthesis VLDL
Microsomal transfer protein Lipid droplet synthesis
Glucose-6-phosphate phosphatase Gluconeogenesis
Fructosebisphosphatase 2 Gluconeogenesis
Carnitine palmitoyl transferase I Fatty acid oxidation
Pyruvate kinase Glycolysis
Malonyl-CoA decarboxylase Fatty acid synthesis
TABLE 5.1: Top 10 ranked enzymes from the kinetic model of central hepatic metabolism
.
Several literature sources were search using a datamining workflow based on KNIME; to ob-
tain information on the important targets from the metabolic network. It was found most
of the targets had no crystal structures (human) as well as known inhibitors. It was found
that inhibition of acetyl-Coa carboxylase (ACC) results in inhibition of fatty acid synthesis
and stimulation of fatty acid oxidation. Therefore, it has the potential to favorably effect
metabolic syndrome 92,93.
On the other hand, carnitine palmitoyl transferase (CPT1) plays an important role in fatty
acid oxidation94, including a rate limiting role by its inhibition by malonyl-CoA 95. Since
CPT1 inhibitors were publicly available with strong affinities values, it was selected as the
first target in the network to investigate further.
5.4 Fatty acid oxidation
The enzymes of involved in fatty acid (FA) oxidation are located in the mitochondrial matrix
in animal cells, as demonstrated by Eugene P.Kennedy and Albert Lehninger 96. The small
chain fatty acids (12 or fewer carbons) can enter the mitochondrial membranes without
membrane transporters. Wheres as, the long chain fatty acids (14 or more carbons) which
constitute the majority of the FA obtained in the diet or released from adipose tissue, cannot
directly enter the mitochondria membranes and hence, they must undergo the three enzy-
matic reactions of the carnitine shuttle 96,97.
The first reaction is catalyzed by a family of isoenzymes present in the outer mitochondrial
membrane, the acyl-CoA snythetases, which promotes the reaction. Thus acyl-CoA syn-
thetase catalyze the formation of a thioester linkage between the fatty acid carboxyl group
and the thiol group of coenzyme A to yield fatty acyl-CoA 96. In the second step fatty acyl-CoA
esters formed at the cytosolic side of the outer mitochondrial membrane are transported to
the inner mitochondrial membrane and oxidized to produce ATP. Fatty acids destined for mi-
tochondrial oxidation are transiently attached to the hydroxyl group of carnitine to form fatty
Chapter 5. Fatty liver drugs and metabolic network 59
acyl-carnitine 96 catalyzed by carnitine acyltransferase I. The fatty acyl-carnitine ester enters
the matrix through the acyl-carnitine transporter of the inner mitochondrial membrane.
In the final step, the fatty acyl group is enzymatically transfered from carnitine to intra-
mitochondrial coenzyme A by carnitine acyltransferase II 96,97. This isoenzyme located on
the inner face of the inner mitochondrial membrane, regenerates fatty acyl-CoA and releases
it, along with free carnitine into the matrix. Carnitine re-enters the membrane space via the
acyl-carnitine/carnitine transporter 96.
This carnitine-mediated entry process is the rate limiting step for oxidation for fatty acids in
mitochondria and plays a regulating role 96.
On the other hand, acetyl-coenzyme A carboxylase 1 (ACC1) and acetyl-coenzyme A carboxy-
lase II (ACC2) plays important role in lipid metabolism. Malonyl- CoA is produced due to
catalysis of the acetyl-CoA by ACC1 in the cytosol and acetyl CoA is utilised via fatty acid syn-
thase (FAS) reactions to generated palmitate, and further utilized in the synthesis of triglyc-
erides (TG) and VLDL. Additionally, acetyl-CoA is carboxylated by ACC2 at the mitochondrial
membrane to form Malonyl CoA; which inhibits the acyltransferases I 93. This inhibition pre-
vents the simultaneous synthesis and degradation of fatty acids 96.
FIGURE 5.1: A schematic representation of the process of fatty acid oxidation The above
figure shows different enzymes involved in the fatty acid oxidation process and their respec-
tive influences in the process.
5.5 Formulation of hypothesis
There are two hypotheses that are postulated in this study and are believed to play important
role in the mechanism of drug induced fatty liver disease. First hypothesis is based on the
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malonyl CoA binding site of the CPT1 A and the second one is based on the carnitine binding
site.
5.5.1 First hypothesis
The first hypothesis is related to the inhibitory activity of malonyl-CoA 97. This is well estab-
lished fact that inhibition of the CPT1 enzyme by malonyl-CoA is key limiting factor in the
process of fatty acid oxidation. This information is used to select drugs which have similar
pharmocophoric properties like malonyl-CoA and therefore could bind to the allosteric site
of the CPT1 and results in its inhibition 98.
Thought it is completely not clear how the mechanism of inhibition of CPT1 takes place by
malonyl-CoA; however many studies have suggested that malonyl binds either through ’A
site’ or ’O site’ of the CPT1 enzyme 97. Therefore, it might interact with the carnitine binding
site of the CPT1 which is important for shuttling of the acetylated fatty acids across other
mitochondrial membrane for oxidation inside the mitochondria 98.
5.5.2 Second hypothesis
CPT1 in its liver isoform has higher affinity for carnitine and it is found that the carnitine
based active site inhibitors are highly studied in literature 95. The unavailability of the crystal
structure of CPT1A isoform makes it difficult to developed the structural based model of the
enzymes and further validate with computational docking studies. However, the class of car-
nitine acyltransferases enzymes which includes acyltransferase (CrAT), Octanoyltransferase
(CrOT) and carnitine palmitoyltransferases (CPTs) are highly homologous. It been suggested
in many studies that the catalytic domains of these enzymes are well conserved, with 35 % or
higher amino acid sequence identity between any pair of them 99.
The carnitine binding site of the CrAT protein is located at one of the entrance of the active
site tunnel 100. The key residues that plays important role in the molecular binding inter-
actions are His322, Tyr 431, Thr 444, Arg 497, Thr 444, Arg 497, Phe 545, Val 548, Ser 433
and two tightly associated water molecules (H20621 and H20679) 100. Among these active sites
residues, His322 is completely conserved in all the carnitine acyltransferases 100. It has been
reported that carnitine binds to the active site of the protein with its beta-hydroxyl moiety
aligned directly with the His322 residue to form a hydrogen bond with the N-3 atom of the
imadazole ring 100. This interactions is important for the catalytic role of the His322, which
has been proposed to deprotonate the beta-hydroxyl group of the carnitine or the thiol group
of the CoA to facilitate nucleophilic attack on the ester linkage of the acyl group 100. Thr 444
interacts with one of the oxygen of the carboxylate group 100. Additionally, other important
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residues in the active sites are Trp81, Tyr86, Tyr431 and Glu 326 binds to carnitine with form-
ing hydrogen bonds 100. It has been reported that hydrogen bonding interaction seems to
be a primary force for the recognition and binding of L-carnitine 100. Moreover, the positive
charge in the carnitine is not required for binding, but it is required for catalysis 100. This pos-
itive charged N atom is important for catalysing the transfer of the acyl group of a long-chain
fatty acyl-CoA from CoA to I-carnitine 100.
Additionally, the alignment of the L-carnitine and His322 is stereo specific and this explains
why D-carnitine is the inactive enantiomer, since the beta-hydroxyl group of the D-carnitine
would point in the opposite direction of Hiss 322 and therefore, would not be accessible for
acyl group transfer 100.
The main assumption here is drugs that are similar to carnitine and have required functional
group for binding may bind in the carnitine binding site of the CPT1. However, lack of bind-
ing which favored the catalytic role of the enzyme by taking into the most important residues
as well as absence of the positively charged N atom, it will not be able to continue catalytic
process and results in no fatty acid transfer for beta-oxidation in the mitochondria and thus,
leading to accumulation of fatty acids outside. This will result in competitive inhibition of
CPT1. One argument in support of this hypothesis can be stated that, Oxfecine and Pisolithin
A (pubchem id :36143; 355) which are structurally very similar to carnitine with an additional
6-membered ring in it; is also an inhibitor of CPT1. On the hand, Emeriamine also known
Amino-carnitine/ Emeriamine (pubchem id:121830) is also an inhibitor of CPT1 as shown in
figure
FIGURE 5.2: Structure of inhibitors of CPT1 similar to carnitine.
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5.6 Data set processing
5.6.1 Pharmacophore model for drugs similar to malonyl CoA
The ligand based pharmacophore model is highly dependent on an accurate and precise se-
lection of training set. In course of data selection it was considered that most, medium and
least active compounds were incorporated in the training set and test as shown in the tables
5.2 and 5.3. A total of 15 training set compounds were selected. The compounds with activity
IC50 value less than 1 mM were considered as most active and rest as medium actives.
7 test compounds were selected for the validation of the pharmacophore model. In the test
compound sets the compounds similar to carnitine (CHEMBL2114397, CHEMBL129918,
CHEMBL75880, CHEMBL1232077, CHEMBL203266) were considered as inactives. This was
done because, the pharmacomodel is based on the malonyl Co-A binding site and so molecules
with higher molecular weight were considered as most actives (This is also confirmed by
the IC 50 values. However, there were two active compounds in the test set (CHEMBL633,
CHEMBL2216773). One of the active compound in the test is amiodarone (CHEMBL633)
with an IC50 value of 140 mM. Amiodarone is considered as one of the classical fatty liver
drugs101.
Number CHEMBL id Pubchem id activity IC50 in mM Pubmed id
1 CHEMBL2216778 16718554 0.016 21504156
2 CHEMBL2216774 25095157 0.02 21504156
3 CHEMBL2216779 15984085 0.02 21504156
4 CHEMBL2216776 66857424 0.026 21504156
5 CHEMBL2216775 16736346 0.065 21504156
6 CHEMBL2216777 124825719 0.165 21504156
7 CHEMBL2216780 11979264 0.19 21504156
8 CHEMBL2216769 71457921 0.24 21504156
9 CHEMBL2216768 23695524 0.25 21504156
10 CHEMBL2216782 71452605 1 21504156
11 CHEMBL2216781 71463291 1 21504156
12 CHEMBL1231506 9843897 1.5 21504156
13 CHEMBL2216785 23729161 1.7 21504156
14 CHEMBL2216771 15234003 2.4 21504156
15 CHEMBL1231507 13671155 2.67 21504156
TABLE 5.2: Training set for pharmacophore model. The table shows the total number of
training set compounds and their activity value
The training set is constructed using information from published source 95. All the inhibitors
were experimented on a same essays and under similar experimental conditions. The chem-
ical structures of the all the 15 training set compounds used for generation of the model is
shown in the figure 5.3 .
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FIGURE 5.3: Structure of ligands in the training set Most of the active compounds are large
molecules and has similar functional groups
Number CHEMBL id Pubchem id activity in mM Pubmed id
1 CHEMBL2114397 121830 76.4 21504156
2 CHEMBL129918 355 >100 21504156
3 CHEMBL75880 4746 >100 21504156
4 CHEMBL1232077 36143 >100 21504156
5 CHEMBL203266 21109 100 21504156
6 CHEMBL633 2157 140 21504156
7 CHEMBL2216773 9893640 51000 21504156
TABLE 5.3: Test set for pharmacophore model. The table shows the total number of test set
compounds and their activity value
The test set compounds were also extracted from the same published literature source and
were experimented in same essays 95. The chemical structures of the all the 7 test set com-
pounds used for generation of the model is shown in the figure 5.4.
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FIGURE 5.4: Structures of the test set. The compounds similar to carnitine and smaller in
size are considered as inactive
5.6.2 Computational docking of drugs similar to carnitine
The data set for this part was extracted from drugbank database. Since the lead compound
was carnitine and the screening dataset includes all approved drugs.
5.6.3 Known fatty liver drug set
Based on data mining and text mining from literature sources with queries like fatty liver,
steotosis, steotohepatitis, liver warning, hepatic warning, drug-induced fatty liver; a total of
12 drugs associated with fatty liver disease were retrieved.
5.7 Methods
In this section two methods for each of the hypotheses have been explained in details.The
pharmacophore based model for predicting drugs that could bind to the malonyl-CoA bind-
ing site of the CPT1 and a computational docking based model for predicting drugs that could
bind to the carnitine binding sites of the CPT1.
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5.7.1 Ligand based pharmacophore modeling of malonyl CoA similar inhibitors
Ligand based pharmacophore model represents a key computational strategy in the absence
of a macromolecular target structure. A common feature pharmacophore model was devel-
oped using information from a set of active compounds for the target CPT1. The model is
heavily dependent on the extraction of the common chemical features from 3D structures
from the set of known ligands which represents essential interactions between the ligands
and the molecular target CPT1. The algorithm behind this model is explained in details in
the section 2.4.
Diverse conformation generation protocol was executed using Discovery Studio software.
The parameters for number of conformers were kept as 300 conformations and an energy
threshold of 29kcal/mol above the global energy minimum were considered f or generating
the conformers. Prior to hypothesis generation, common pharmacophore features amongst
the active training set compounds were analyzed using automatic pharmacophore genera-
tion protocol in Discovery studio as shown in figure 5.5 .
FIGURE 5.5: Common pharmacophoric features present in the training set The negative
ionisable feauture is shown in blue, hhydrophobic feature is cyan and ring aromativ feature
in orange
The qualitative top ten hypotheses were generated based on the training set active molecules
using the Common Features Pharmacophore Generation in Discovery Studio. The common
feature were identified which are necessary to inhibit CPT1. The direct hit value of ’1’ and
partial hit value ’0’ indicates that the molecules present in dataset are well mapped to all
the chemical features in the hypothesis and there is no partial partial mapping or missing
features as specified in the table 5.4. The external validation result are shown in the table
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5.5. According to the external validation results all the four hypotheses (1,2,3,4) were able to
predict the true actives with sensitivity 1 and specificity 0.80. The best hypothesis (Hypo1)
and its pharmacophore features were chosen to predict new compounds that could inhibit
CPT1.
Model Features Rank Direct Hit Partial Hit Max Fit
Hypo1 ZHH 118.97 111111111111111 000000000000000 3
Hypo2 ZHH 118.24 111111111111111 000000000000000 3
Hypo3 ZHH 117.97 111111111111111 000000000000000 3
Hypo4 ZHH 117.57 111111111111111 000000000000000 3
Hypo5 ZHA 116.17 011111111111111 100000000000000 3
Hypo6 ZHA 116.17 011111111111111 100000000000000 3
Hypo7 ZHA 115.44 011111111111111 100000000000000 3
Hypo8 ZHA 115.44 011111111111111 100000000000000 3
Hypo9 ZHA 115.17 011111111111111 100000000000000 3
Hypo10 ZHA 115.17 011111111111111 100000000000000 3
TABLE 5.4: The result of top 10 hypotheses generated by HipHop program. Three features
were found to be most common on the active compounds in the training set, one feature
corresponds to ‘hydrophobic’ (Z) and two features corresponding to ‘hydrogen bond ac-
ceptor lipid’ (H). The higher ranking scores indicates the lesser the probability of chance
correlation. The best hypothesis is indicated with the highest value
Pharmacophore number of actives number of inactives Sensitivity Specificity
Hypo1 2 5 1 0.80
Hypo2 2 5 1 0.80
Hypo3 2 5 1 0.80
Hypo4 2 5 1 0.80
Hypo5 2 5 0.50 0.60
Hypo6 2 5 0.50 0.60
Hypo7 2 5 0.50 0.60
Hypo8 2 5 0.50 0.60
Hypo9 2 5 0.50 0.60
Hypo10 2 5 0.50 0.60
TABLE 5.5: Validation of the all the ten hypotheses on an external validation set.
To understand how the actives and least actives were mapped with the pharmacophore fea-
tures generated by Hypo1, all the training set compounds were visualized individually and
their mapping were noted. Some of the most actives training compound and least active
training compounds mapped with the pharmacophore features of Hypo1 are shown in the
figures
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(A) Pharmacophores of molecule ‘16718554’ (B) Pharmacophores of molecule ‘24825719’
FIGURE 5.6: Pharmacophore alignment with the active training set molecules
(A) Pharmacophores of molecule ‘13671155’
(B) Pharmacophores of molecule‘15234003’
FIGURE 5.7: Pharmacophore alignment with the least active training set molecules
Furthermore, the small set of already known fatty liver which was extracted from literature
sources using text mining, were mapped with the pharmacophoric features of the hypo1.
Out of 12 compounds in the fatty liver drug set, 4 compounds were able to mapped as shown
in the figure 5.8 .
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FIGURE 5.8: Common pharmacophoric features of Hypo1 to the known fatty liver drugs,
The hydrophobic feature is indicated in cyan and hydrogen bond acceptor lipid shown in
green. Fatty liver drugs represented in this set are amiodarone, methrotrexate, tamoxifen
and diltiazem
5.7.2 Computational molecular docking based on carnitine similar inhibitors
The structural homology model of CPT1 has been developed based on the mouse CrAT crys-
tal structure 102. Since the crystal structure of human CrAT protein was available (pdb ID:1S5O),
this structure was used for the computational docking studies in this thesis. The assumption
in this study is since the carnitine binding site of the class of carnitine acyltransferases en-
zymes are highly conserved, so drugs binding to carnitine binding site of the CrAT protein
may also bind to the carnitine binding site of the CPT1.
In order to screen drugs similar to carnitine, two different search methods were implemented.
It is previously known that hydroxyl group and both the oxygen of the carboxylate group of
carnitine are important for binding. This information was used for a local search criteria.
Carnitine molecule was fragmented into 54 fragments with minimum fragment length of 3
atoms to maximum fragment length of 7 atoms. The fragments were further reduced to four
by considering only those patterns (functional groups) which were important for binding.
These four fragments were used for substructure search 103 against the set of approved drugs.
The substructure search were computed using exact atom charges and stereo match. Each of
the drug containing any one of the fragments were given a score of 1.
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Carnitine fragments
A global similarity score was calculated between carnitine and approved drugs using MACCS
molecular fingerprint based similarity search. Tanimoto score was considered as the measure
of global similarity with a threshold of 0.50 and above.
Name Pubchem id FragScore GlobalScore
Hydroxybutanoate 3037032 1 0.70
Cefepime 5479537 1 0.60
Ceftazidime 5481173 1 0.50
Methacholine 1993 1 0.84
Bethanechol 2370 1 0.63
Valproate 3121 1 0.68
Bromfenac 60726 1 0.55
Ibuprofen 3672 1 0.56
TABLE 5.6: Screened drugs based on fragment and similarity search scoring.
Molecular docking of the screened drugs into the binding site of CrAT were performed us-
ing Gold docking software and GoldScore scoring function. The active site cavity was set
to 6 Å).The docking results were further visually analyzed using PyMol software and ligand
interactions plots were obtained using Discovery Studio software.
5.8 Results
The results obtained from two different methods based on different hypotheses are reported
in the individual sections below.
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5.8.1 Results of pharmacophore model
The Hypo1 which was ranked as the best hypothesis was considered to as query for predicting
new drugs that could inhibit CPT1. All the approved drugs set from DrugBank were consid-
ered as a dataset. The multiple conformers of this dataset were computed using best con-
firmation generation protocol in the discovery studio. The pharmocophoric features of the
Hypo1 were mapped with the approved drug set. The resulting molecules were ranked ac-
cording to their geometric fit value that indicates how well the molecules were mapped onto
the hypothesis features location constraints and their distance deviation from the feature
centers. The compounds with the highest fit values are suggested for experimental valida-
tion.
Out of 2399 FDA approved drugs in drug bank database, 100 drugs were mapped with the
pharmacophore features with best fit value of 2. 86 and above. The max fit value achieved
by the screen drugs was 2.99. The top 30 drugs were further shortlisted based on the best fit
value as shown in the table 5.7 .
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Number Name Pubmed id Fit value Therapeutic area
1 Nafarelin 25077649 2.991 Gonadotropin-releasing hormones
2 Carfilzomib 11556711 2.991 Antineoplastic agents
3 Fexofenadine 3348 2.990 Respiratory system
4 Ibutilide 607536 2.990 Antiarrhythmics
5 Epoprostenol 5280427 2.989 Antithrombotic agents
6 Ritonavir 392622 2.989 HIV protease inhibitor
7 Treprostinil 6918140 2.988 Antithrombotic agents
8 Atazanavir 148192 2.980 HIV protease inhibitor
9 Raltitrexed 104758 2.980 Antineoplastic agents
10 Azilsartan medoxomil 11238823 2.971 Cardiovascular system
11 Dirigestran 36523 2.963 Gonadotropin-releasing hormones
12 Xarator 4636594 2.960 Cardiovascular system
13 Formoterol 3410 2.947 Respiratory system
14 Haloperidol 3559 2.947 Anti-psychotic
15 Eltrombopag 9846180 2.931 Antihemorrhagics
16 Dabigatran Etexilate 6445226 2.93 Antithrombotic agents
17 Montelukast 5281040 2.914 Leukotriene receptor antagonists
18 Bosentan 104865 2.907 Antihypertensives
19 Terlipressin 72081 2.895 Vasopressin and analogues
20 Desmopressin 16051933 2.895 Vasopressin and analogues
21 Ximelagatran 18670936 2.890 Antithrombotic agents
22 Zafirlukast 5717 2.890 Leukotriene receptor antagonists
23 Tipranavir 54682461 2.890 Protease inhibitors
24 Tamsulosin 129211 2.890 Alpha-adrenoreceptor antagonists
245 Amiodarone 2157 2.890 Antiarrhythmics
26 Salmeterol 5152 2.890 Respiratory system
27 Cromolyn 2882 2.890 Anti-inflammatory
28 Benziodarone 6237 2.889 Cardiovascular system
29 Glimepiride 3476 2.889 antidiabetic
30 Methotrexate 126941 2.889 Antineoplastic agents
TABLE 5.7: Top 30 screened drugs with highest fit values predicted by model based on
Hypo1.
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5.8.2 Results of computational docking
Based on the molecular docking experiments final three drugs are suggested that can bind to
the carnitine binding site of CPT1. Upon binding of these drugs, carnitine dependent transfer
of the fatty acid into the mitochondria will be affected and hence result in fats accumulation.
(A) Carnitine binding to the CrAT protein (B) Ligand interaction diagram of carnitine and CrAT
FIGURE 5.9: Carnitine binding interaction with CrAT protein
Cefemine (yellow) as shown in the figure 5.10, binds to the active site of CrAT (blue). The
ligand interaction analysis of cefepime with CrAT protein shows that the oxygen of the car-
boxylate group of cefepime interacts with Tyr320 residue of the protein forming hydrogen
bond interactions. Similarly, the terminal nitrogen of the cefepime interacts with Gly546 and
Tyr421 residues of the protein.
(A) Cefepime binding to the CrAT protein
(B) Ligand interaction diagram of cefepime and
CrAT
FIGURE 5.10: Cefepime binding interaction with CrAT protein
Ceftazidime (red) as shown in the figure 5.11, binds to the active site of the CrAT (blue).
From the ligand interaction diagram it can be seen that nitrogen of ceftazidime interacts with
Ser433 residue of the protein forming hydrogen bond interaction. Additionally, the terminal
nitrogen of ceftazidime interacts with Met543 and Tyr320 of the protein.
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(A) Ceftazidime binding to the CrAT protein (B) Ligand interaction diagram of Ceftazidime and CrAT
FIGURE 5.11: Ceftazidime binding interaction with CrAT protein
Bromfenac (purple) as shown in the figure 5.12, binds to the active site of the CrAT protein
(blue). The ligand interaction plot shows the nitrogen of the bromfenac interacts with His322
residue of the protein forming hydrogen bond interaction. The terminal ring of the brom-
fenac forms pi-sigma interaction with Phe545 residue of the protein.
(A) Bromfenac binding to the CrAT protein (B) Ligand interaction diagram of bromfenac and CrAT
FIGURE 5.12: Bromfenac binding interaction with CrAT protein
5.9 Predicted fatty liver drugs
According to the liver tox database of NIH (http://livertox.nih.gov/Phenotypes_Fatty.
html), most of the the medications commonly implicated in causing fatty liver includes anti-
depressant, cortico steroids, anti-psychotic, antiarrhythmic, antineoplastic drugs such as
amiadorone, tamoxifen, methotrexate 101. One of the reason for side-effects of a drug in
the non-selective binding to other target besides the intended therapeutic target. Human
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genome project revealed biggest number of large paralog families among all sequenced or-
ganisms. Since, the paralogous proteins have similar structure, a drug that targets one para-
log is likely to bind to other paralogs too. However, the affinity towards these off-targets (par-
alogs) can be lower than to the intended therapeutic molecular target ; but with the increase
of dose and duration of the administration of the drugs , affinity to off-targets will increase
and can be high enough to mediate side effects. So, based on the therapeutic index area
and daily dose of administration of the drugs (http://www.whocc.no/atc_ddd_index/),
the final list of 23 drugs predicted using pharmacophore model are planned for experimental
validation as shown in the table 5.8 .
Number Name Pubmed id Fit value Therapeutic area
1 Carfilzomib 11556711 2.991 Antineoplastic agents
2 Fexofenadine 3348 2.990 Respiratory system
3 Ibutilide 607536 2.990 Antiarrhythmics
4 Epoprostenol 5280427 2.989 Antithrombotic agents
5 Ritonavir 392622 2.989 HIV protease inhibitor
6 Treprostinil 6918140 2.988 Antithrombotic agents
7 Raltitrexed 104758 2.980 Antineoplastic agents
8 Dirigestran 36523 2.963 Gonadotropin-releasing hormones
9 Xarator 4636594 2.960 Cardiovascular system
10 Formoterol 3410 2.947 Respiratory system
11 Haloperidol 3559 2.947 Anti-psychotic
12 Eltrombopag 9846180 2.931 Antihemorrhagics
13 Dabigatran Etexilate 6445226 2.93 Antithrombotic agents
14 Montelukast 5281040 2.914 Leukotriene receptor antagonists
15 Bosentan 104865 2.907 Antihypertensives
16 Terlipressin 72081 2.895 Vasopressin and analogues
17 Ximelagatran 18670936 2.890 Antithrombotic agents
18 Zafirlukast 5717 2.890 Leukotriene receptor antagonists
19 Tipranavir 54682461 2.890 Protease inhibitors
20 Tamsulosin 129211 2.890 Alpha-adrenoreceptor antagonists
21 Cromolyn 2882 2.890 Anti-inflammatory
22 Benziodarone 6237 2.889 Cardiovascular system
23 Glimepiride 3476 2.889 antidiabetic
TABLE 5.8: Top 30 screened drugs with highest fit values predicted by model based on
Hypo1.
Based on the integration of fragments score (local), similarity score (global) and molecular
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docking studies, three new drugs are suggested that could bind to the carnitine binding site
of the CPT1 as shown in the table 5.9 .
Name Pubchem id FragScore GlobalScore Therapeutic area
Cefepime 5479537 1 0.60 Antibacterial
Ceftazidime 5481173 1 0.50 Antibacterial
Bromfenac 60726 1 0.55 Anti-inflammatory
TABLE 5.9: Fatty liver drugs predicted using molecular docking studies into the carnitine
binding site of the CrAT protein.
5.10 Discussion
In this study, a novel approach to detect fatty liver drugs using metabolic network based tar-
get selection and computational molecular modeling method had been reported. The im-
portant targets that play important role in the fatty acid metabolism have been identified
using the kinetic modeling of the central hepatic metabolism. Out of the eight top ranked
target, CPT1 was selected for further investigation and computational modeling studies. The
inhibitors of the CPT1 were selected from the chembl database (ref) and two different hy-
pothesis were proposed. First hypothesis was proposed to predict drugs that could bind to
the malonly-CoA binding site of the CPT1 and there by result in no beta-oxidation of the fatty
acids. The inhibitors of CPT1 liver isoform in humans were used to create common feature
based pharmacophore model. The inhibitors were obtained from the same source (tested
in the same assays) and therefore serves as gold standard to generate the model. All the in-
hibitors had strong activity value as shown in the table 5.2, a close inspection of the structures
of these actives inhibitors in the training set reveals all these compounds three common fea-
tures such as one hydrophobic group and two hydrogen bond acceptor lipid groups with an
interfeature distance less than 2.5 Å. On comparison of the functional groups of these actives
sets confirms the carboxyl group which denotes the hydrogen bond acceptor lipid are im-
portant for the interaction with the enzyme pocket. However, having heterocyclic ring in the
structure makes them hydrophobic and which is essential for it to be transported to the site
of action by diffusion across membranes. Additionally, it was also noticed that some of in-
hibitors of the CPT1 have structural similarity with carnitine, supporting the second hypoth-
esis in this study can be true. The 12 known fatty liver drugs were mapped to the common
feature pharmacophore model, out of which 5 drugs were mapped as shown in the figure 5.8
. Amiodarone which is one of the classical fatty liver is also a inhibitor of CPT1, this supports
our hypothesis that drugs inhibiting CPT1 can results in fatty liver syndrome. Based on the
pharmacophore model 100 approved drugs were predicted to have similar pharmacophoric
features like that of CPT1 inhibitors with individual fit value. Top 30 drugs were selected hav-
ing highest fit value. It is commonly observed that binding affinity of drugs to the intended
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molecular target is much higher than to their off-targets. Therefore, it may be possible that
drugs that are administrated at higher doses at regular interval can induce fatty liver much
faster that the drugs that are taken for a short duration and in less quantity. So considering
the daily administrative dose as well as therapeutic area, 23 final drugs were selected which
are suggested for experimental validation as shown in the table tab:pharmdrugs.
Molecular docking studies of the drugs predicted using the fragments and similarity search
method reveals that drugs can also bind to the carnitine-binding site of the protein resulting
in competitive inhibition. According to the second hypothesis, three drugs were predicted.
Since, the crystal structure of the CPT1 was not available, the structure of human CrAT pro-
tein was used for molecular docking studies as shown in the table 5.9. One of the main short-
coming of this investigation is unavailability of the CPT1 structure, it is therefore difficult
to predict how exactly the carnitine similar analogues can bind to CPT1 in a real biological
system.
5.11 Conclusion
As illustrated above, the approach presented in this chapter is a novel way to determine tar-
get, drugs and the mechanism involved in drug-induced fatty liver syndrome. The unique-
ness of this approach includes the consideration of different layers of information: selec-
tion of targets using a kinetic model of the central hepatic metabolism, generating of models
based on the pharmacophores as well as ligand-protein interaction. Beyond the prediction
of potential target for fatty liver and the mechanism involved, the modeling approach pre-
sented in this study is expected to open up many additional exciting possibilities in the near
future, for e.g data on drugs-target interactions may be integrated with the kinetic model to
further enhance the model’s accuracy.
The combination of computational system biology, structural bioinformatics and chemin-
formatics based approach as presented in this study could become indispensable tool dur-
ing the pre-clinical and clinical phases of new-drug development for studying the nature of
adverse side-effects.
Chapter 6
Prediction of drugs interacting with
HLA alleles
6.1 Introduction
Adverse drugs reactions (ADRs) remain a significant source of patient morbidity through-
out the world 104 . ADRs can be broadly classified into two types: such as type A reactions
which are often considered as predictable, common and related to the drug’s pharmaco-
logical activity and type B reactions also known as ‘Idiosyncratic drug reactions’ which are
mostly unpredictable and not related to the drug’s pharmacological actions. Type B reac-
tions includes drug intolerance reactions (e.g asthma) and immune mediated adverse drugs
reactions (IM-ADRs) also known as drug hypersensitivity reactions 105. IM-ADRs are among
the most difficult type of ADRs to predict. The human leukocyte antigen (HLA) is well known
for its association with certain diseases like ankylosing spondylitis, celiac disease and many
others. Recently, based on clinical studies it was established such reactions based on im-
mune mechanisms have genetic associations and strong linkages between drug hypersen-
sitivity reactions to several drugs and HLA alleles have been identified 106. The discovery of
new associations between drug toxicities and specific HLA alleles has been well documented
for immunologically mediated reactions associated with the use of abacavir in patients ex-
pressing the HLA molecular variant B*57:01 107. HLA- B*57:01, like other HLA alleles, is not
equally represented among all ethnic populations as shown in the table 6.1 .
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TABLE 6.1: Allele frequencies in various populations (Meyer et, al., 2007).
Population B*57:01 (%) B*15:02 (%) B*58:01 (%)
Cuacasian 3.3 <1 0.8
Sub-Saharan African 1 <1 5.8
Han Chinese <1 10.2 7
Puyuma <1 18 <1
Okinawan <1 <1 <1
Singapore <1 11.6 5.8
Korean <1 0.5 5.5
The significance of these discoveries has led the European Medicine Agency (EMA), the USA
Food and Drug Administration (FDA) and other regulatory agencies to recommend HLA based
gene testing before initiation of drug treatment 108 . Abacavir (cyclopropylaminopurinylcy-
clopentane: ABC) is a structural analogue of guanosine and reverse transcriptase inhibitor
which is used in the treatment of human immunodeficiency virus (HIV) infection and the
acquired immunodeficiency syndrome (AIDS). It has been reported that in approximately 8
% of the patients, abacavir is associated with significant immune-mediated drug hypersensi-
tivity, which is strongly associated with the presence of the HLA-B*57:01 allele 109 . Abacavir
is a deoxy-guanosine base and is metabolized into carbovir triphosphate 110 . Though aba-
cavir is metabolized by the liver, it does not inhibit or induce cytochrome P-450 enzymes and
does not interact with medications metabolized by cytochromes 108 .
Three most important complementary models for the immune-mediated severe drugs re-
actions mechanism have been reported 105. The pro-hapten (or hapten model) states that
chemically inert drug may result in reactive metabolites and therefore induce an immune re-
sponse by modifying host’s self-proteins and forming de novo antigens complexes 111 . The
p-i concept which is based on the pharmacologic interactions with immune receptors states
that a chemically inert drug can activate T-cell response if they exhibit high affinity to T-
cells receptors (TCR) or major histocompatibility complex (MHC) molecules 112. The danger
model states the danger signals such as chemical, physical or viral stress other than drugs
are involved in overcoming the immune tolerance barriers 113. However, the most convinc-
ing mechanisms was described by McCluskey group 106 . Human leukocyte antigen class I-
restricted activation of CD8 + T cells provides the immunogenetic basis of a systemic drug
hypersensitivity.Immunity 28:822–832), which states that the activation of CD8+ cells in a
strictly HLA-B*57:01-restricted manner is associated with abacavir induced adverse drugs
reactions. Following the mechanism proposed by Illing, et.al 106. an alternative hypothesis
‘’altered self-repertoire’ hypothesis as a mechanism for drug hypersensitivity is explained by
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Peters group107 . According to Ostrov,et.al 107, the binding groove of HLA-B*57:01 can accom-
modate abacavir and hence alter the repertoire of self-peptide proteins that are bound and
presented to T-cell receptors eliciting immune response.
In the earlier study reported by Ostrov,et.al 107, it was illustrated that abacavir interacts with
the residues in the F-pocket of HLA-B*57:01 and is in contact with the side-chain of the C-
terminal residue of the bound peptide. This type of binding of abacavir with HLA specific
antigen (HLA-B*57:01) results in an alteration of its specificity for self-peptides. In this study,
the mechanism proposed by Peters group was considered as the standard mechanism to
develop a in silico prediction protocol for drugs which are structurally similar to abacavir
and may bind to HLA-B*57:01 in a similar manner and therefore could result in immune re-
sponse.
6.2 Methods
In this study, a protocol has been designed which is based on the Abacavir-HLA-B*57:01 in-
teractions (ligand-receptor). The initial step involves analysis of the key residues involved in
the interaction of the abacavir-HLA complex and therefore identifying the pharmacophoric
groups. Two-dimensional (2D) and three-dimensional (3D) similarity search were imple-
mented to filter drugs having structural similarities with abacavir. The screened drugs were
docked into the binding cavity of HLA-B*57:01 considering abacavir as the standard ligand.
The molecular docking study results were analyzed and suggested for experimental valida-
tion. The workflow is shown in the figure 6.1.
6.2.1 Analysis of pharmacophoric groups
To identify the key residues involved in the interaction of Abacavir with the HLA complex a
pharmacophore based feature mapping was developed using the automatic pharmacophore
generation option of the Discovery Studio software. The crystal structure of the HLA-abacavir
complex (PDB id: 3UPR) was used and 10 features pharmacophore of ligand (abacavir) was
generated. The features includes two hydrogen bond acceptor, six hydrogen bond donor, one
hydrophobic and one ring-aromatic. In abacavir, cyclo propyl moiety has hydrogen donor
features, cyclopentenyl moiety has both hydrogen donor and hydrophobic features whereas
the 2-amino purine moiety contains hydrogen acceptor, hydrogen donor and ring aromatic
features as shown in the figure 6.2 .
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FIGURE 6.1: A diagrammatic representation of the protocol for prediction 115.
FIGURE 6.2: Pharmacophoric features of abacavir.The hydrogen acceptors shown in green,
hydrogen donor in magenta, hydrophobic feature in cyan and orange represents the ring-
aromatic feature.
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6.2.2 Similarity based screening
The structure of the lead molecule abacavir was compared with database molecules based on
2D similarity and 3D similarity. In this study, zinc database was screened using 2D similarity
search based on a concatenated fingerprint consisting of the ’FP2’ and ’FP4’ fingerprints of
MyChem as explained in the sections 3.3.1 and 3.4.1 . The structural similarity score was
calculated using Tanimoto index 44 , where 0 means no similarity and 1 means maximum
similarity. A total of 10,000 molecules were screened considering a threshold of 0.60 and
above.
Furthermore, these 10,000 molecules were further compared with abacavir based on their
3D similarity. The 3D similarity was performed using a superimposition algorithm devel-
oped previously in the group 114. The 3D similarity scoring is based on the root mean square
deviation (rmsd) function which takes into account the distance between the atoms. This
score reflects the degree of superimposition between the query molecule (abacavir) and the
database entries. Using the 3D scores with a threshold of rmsd less than 1.5 Å, a total of 2000,
compounds were screened.
The purine core of abacavir was observed to be important from the crystal structure of the
complex (PDB code: 3UPR). Accordingly, the purine core was marked as one of the chemi-
cal features to be retained in the screened drugs. Similarly, the hydroxyl group of abacavir
was hypothesized to be actively involved in the binding preference. Moreover, it was also an-
alyzed from the crystal structure that the spatial arrangement of the aromatic ring is an im-
portant recognition element. The pharmacophoric features and important functional groups
of abacavir involved in the interactions with the receptor were considered to further optimize
the screening pipeline which consists of 153 compounds. These 153 compounds were further
reduced to 54 compounds by selecting only approved drugs and special preference to anti-
viral drugs (i,e drugs from the same therapeutic class as abacavir). Finally, with reference
to the chemical tractability and the quality of superimpositions, 54 compounds (structurally
similar to abacavir) were docked into the binding cavity of the HLA complex.
In the table 6.2 the 2D similarity and 3D similarity scores are reported with the respective
RMSD and alignment scores of individual drugs compared to abacavir. These score were
recalculated using KNIME while preparing this thesis.
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TABLE 6.2: 2D similarity and 3D similarity scores
Pubchem ID Name 2D scores 3D scores RMSD Alligment scores
441300 Abacavir 1 1 0 126.68
2422 Bohemine 0.77 0.67 0.33 106.70
160355 Roscovitine 0.72 0.65 0.53 96.96
20279 Cladribine 0.64 0.43 0.48 114.40
2022 Acyclovir 0.61 0.36 0.591 95.208
3011155 Arranon 0.61 0.45 0.55 104.30
14978 Sangivamycin 0.60 0.44 0.61 106.09
4201 Minoxidil 0.50 0.40 0.56 88. 913
6.2.3 Molecular docking
Molecular docking was performed to probe the binding sites of the 54 selected drugs into
HLA-B*57:01. The 2D structures of the molecules were cleaned and water molecules or salts
attached were removed. The 3D coordinates of the molecules were created using the Dis-
covery Studio software . Computational docking was performed using GOLD 5.2 (Genetic
Optimization for Ligand Docking) and the GOLDScore scoring function. The crystal struc-
ture of HLA-B*57:01 (abacavir-induced MHC complex) having PDB ID: 3UPR was selected
as the standard structure for docking. The original ligand (abacavir) confirmation and cavity
was used to defined the active binding site (radius 10.0 Å), which also includes the the pep-
tide binding area of the HLA-B*57:01 molecule. GOLD docking software permits full ligand
flexibility and partial protein flexibility for a maximum of ten user defined residues including
both backbone and side chain residues. All other additional standard parameters were kept
default.
6.2.3.1 Analysis of docking results
The docking results were visually inspected using PyMOL(The PyMOL Molecular Graphics
System, Version 1.5.0.4 Schröndinger , LLC). The drugs that failed to bind into the defined
binding site were ignored and were not considered for further screening. The 2D ligand-
interaction diagram for each pose of the drugs were created using Discovery Studio software
and interactions with key residues within the binding site of the HLA-B*57:01 molecules were
noted. Based on standard ligand interactions and reasonable binding conformations, seven
candidates were forwarded as leads for experimental validation.
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The drugs roscovitine, cladribine, acyclovir, arranon, minoxodil, sangivamycin and bohem-
ine were selected as final drugs for in vitro experiment. All the drugs contained purine core
as well as the hydroxyl group important for binding, except minoxidil which was selected as
negative control as shown in the figure 6.3 .
FIGURE 6.3: Seven drugs as leads obtained after molecular docking studies 115 . The
purine core in highlighted in green box and the hydroxyl group in red circle. The picture
was taken from the publication
6.3 Results
Computational identifications of approved drugs which are structurally similar to abacavir
was based on the assumption ’structurally similar drugs should have similar biological ac-
tivities’. Additionally, further layers of information like pharmacophoric groups and binding
interactions with the HLA-B*57:01 molecule were also added into the prediction pipeline.
The prediction pipeline includes screening of ZINC database based on 2D and 3D similarity-
based method followed by pharmacophore based filtering. In order to reduce the huge chem-
ical space of ZINC database, a threshold of 0.60 Tanimoto score was considered. Based on the
chemical tractability and reasonable binding interactions, the enriched subset was docked
into the HLA- B*57:01 active site using computational docking. Docking results were visually
inspected and analyzed in detailed to screen the final seven drugs.
Previous studies 107 revealed that abacavir binds to peptide binding groove of HLA- B*57:01
interacting with the Ser166, Asp 114, Ile 124 and Tyr74 of the HLA molecule. Additionally,
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it was observed that the purine core of abacavir plays a crucial role in the molecular recog-
nition. Therefore, all the information was considered for pose selection from the molecular
docking studies.
Visual inspection of the docking poses in terms of the ligand-receptor interactions, maxi-
mum similarity between the reference structure (abacavir) and the database entries as well
as the occupancy and conformation of the screened drugs into the defined active site of the
HLA- B*57:01 molecule led to the prediction of seven drugs as candidates for experimental
studies.
Drugs Therapeutic class
Roscovitine antineoplastic
Cladribine antineoplastic
Acyclovir antiviral
Arranon antineoplastic
Minoxodil vasodilator
Sangivamycin antibiotic
Bohemine kinase inhibitor
6.3.1 Computational validation
The computational docking studies revealed that acyclovir binds to HLA- B*57:01 molecule
similarly to abacavir. Like abacavir, acyclovir too occupies the floor of the peptide binding
groove of HLA- B*57:01 molecule as shown in the figure 6.4 . This kind of arrangement is im-
portant in order to increase the affinity of certain self peptides resulting in an altered peptide-
binding repertoire as identified in the previous study 115.
Furthermore, analysis of the ligand-receptor interaction diagram of acyclovir- HLA- B*57:01
complex obtained from docking studies shows that acyclovir interacts with the same residues
of the HLA- B*57:01 molecule as observed in abacavir- HLA- B*57:01 complex. Acyclovir
forms hydrogen bond interactions with the side-chains of Ser 116, Asp 114 and Tyr118 of
HLA- B*57:01 molecule. Additionally, there is a Pi interaction with Trp 147, Tyr74 of HLA-
B*57:01 molecule as shown in the figure 6.5 .
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(A) Abacavir binding to HLA- B*57:01 (B) Acyclovir binding to HLA- B*57:01
FIGURE 6.4: Computational identification of binding site for acyclovir in HLA- B*57:01
similar to abacavir Abacavir (left) shown in green and acyclovir (right) shown in blue bind-
ing to the F-pocket of HLA- B*57:01 which are typically in contact with the side chain of the
C-terminal residue of the bound peptide shown in orange 115 .
FIGURE 6.5: Ligand interaction diagram of acyclovir-HLA- B*57:01 complex. Hydrogen
bond interactions between the Ile 124 (MHC molecule) main chains and acyclovir is repre-
sented by green dashed arrow. Hydrogen bond interactions between side-chains of Ser 116,
Asp 114 (MHC molecule) and acyclovir is represented by blue dashed arrow. Pi interactions
between the Trp147, Tyr74 of the MHC molecule and acyclovir is shown in orange line.
In addition, examination of the Ramchandran plot116 of the back bone angles of the crystal
structure of HLA- B*57:01 molecule before and after molecular docking with acyclovir reveals
that they both fall into the commonly observed regions of the psi-phi space as shown in the
figure 6.6 . The percentage of residues in the favored region and allowed region is 96.9 %
and 3.1 % respectively, for both the structures. Whereas, there were no residues in the outlier
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region. This indicates the absence of any steric clashes or distortion in the protein structure
after docking of acyclovir into the peptide binding groove of HLA- B*57:01 molecule.
(A) Protein report of the crystal structure (B) Protein report after molecular docking
FIGURE 6.6: Ramchandran plot for HLA- B*57:01 molecule before and after docking with
acyclovir. The most favored and favoured region are indicated with blue and pink colors,
respectively. The disallowed region is in white color.
6.3.2 Experimental validation
In the experimental analysis, each of the seven predicted drugs were tested in order to con-
firm if their presence could enhance the HLA- B*57:01 binding affinity for three 9-mer pep-
tides with a C-terminal valine, which is known to bind HLA- B*57:01 with high affinity only
in presence of abacavir. This analysis revealed that acyclovir has consistent increase in HLA-
B*57:01 affinity in presence of these three peptides, while the other six drugs have smaller or
no effects at all. Though it was found that acyclovir interacts with the HLA- B*57:01 molecule
in a similar manner as abacavir, it was suggested that under in-vitro conditions, acyclovir
does not have the capacity to stimulate T-cells. The experimental studies were carried out by
Peters and group, at Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunol-
ogy, California, United States of America. Further information on the experimental studies
and procedure can be obtained from the published work 115 .
6.4 Conclusion
Identification of drugs candidates associated with IM-ADRs is an important step in drug de-
sign and development. Peters and group 107 recently proposed a novel mechanism through
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which abacavir interacts with HLA- B*57:01 molecule leading to an alteration of the speci-
ficity of HLA- B*57:01 for self-peptides and associated immune mediated T-cell hypersensi-
tivity reaction . This hypothesis is termed as ’altered self-repertoire’ hypothesis. In this study,
this hypothesis was used to screen drugs that could have potential effects on the self-peptide
repertoire. In silico prediction method was developed considering abacavir as the lead struc-
ture and to predict drugs that are structurally similar to abacavir. Since, the crystal structure
of abacavir-HLA- B*57:01 complex was available, screened drugs were further investigated
based on molecular docking experiments. Six drugs which were structurally similar to aba-
cavir and one drug (minoxidil) having similar pharmacophric groups but structurally less
similar to abacvir; were suggested for in vitro experiments. Of the panel of seven drugs tested
in the in vitro studies, acyclovir was found to have the strongest effect and alter the binding
specificity and ligand repertoire of HLA- B*57:01 molecule. This effect produced by acyclovir
was in a qualitatively similar manner as abacavir, however quantitatively to a much lower
degree. Acylcovir is structurally similar to abacavir, also a guanosine analogue, and shares a
Tanimoto similarity score with abacavir above 0.80. They both are from the same therapeutic
area (i.e antiviral agent).
In this study, it was possible to established an in silico screening protocol taking into account
the structural similarity measure, pharmocophoric features and supported by computational
validation which lead to a novel finding that drug acyclovir that binds to peptide binding
groove of HLA- B*57:01 molecule.
In the in vitro experiments, quantitatively the presence of acyclovir led to 2-3 fold increases
in binding affinity as measured in IC50 where as abacavir led to a 1,000 fold increase in IC50
values for individual peptides and large number of peptides presented exclusively in the pres-
ence of the drug. Acyclovir have a safety profile and the effects of the magnitude observed
here are below the threshold to induced IM-ADRs. However, this study establishes a first
estimate of a threshold of what can be considered a safe in the experimental essays 115.
Chapter 7
Summary
7.1 Summary
Exposure to various chemicals agents through cosmetics, medications, preserved food, en-
vironments and many other sources have resulted in serious health issues in humans. Ad-
ditionally, regulatory authorities from Europe and United States of America have recognized
the risk associated with combined exposure to multiple chemicals. Testing all possible com-
binations of these thousands of compounds is impractical and time consuming. The main
aim of the thesis is to address the problem of off-targets effects of chemical structures by ap-
plying and developing cheminformatics, structural bioinformatics and computational sys-
tems biology approaches.
This dissertation is divided into four main projects representing four different computational
methods to aid different level of toxicological investigations.
In project I (chapter 3) a novel ensemble approach based on the structural similarity of the
chemical compounds and identifications of toxic fragments was implemented to predict ro-
dent oral toxicity. This approach showed powerful and consistently best performance over
available commercial as well as other public methods.
In project II (chapter 4) different machine learning models were developed and compared
using Tox 21 challenge 2014 data, to predict the outcomes of the compounds that have the
potential to interact with the targets active in toxicological pathways. The methods proposed
in this study can be used by the regulatory agencies to access the toxicity of these target spe-
cific compounds in large scale.
In project III (chapter 5) a novel approach integrating the trio concept of ’computational
system biology, cheminformatics and structural bioinformatics’ to predict drugs induced
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metabolic syndrome have been described. Two different novel mechanisms for drug induced
fatty liver syndrome has been proposed and computationally validated.
In project IV (chapter 6) a in silico screening protocol was established taking into the struc-
turally similarity, pharmacophoric features and validation using computational docking stud-
ies. This approach led to the identification of novel binding site for acyclovir in the peptide
binding groove of the human leukocyte antigen (HLA) specific allele. Such specific binding
of drugs to the specific HLA alleles results in immune-mediated adverse drug reactions.
The over all contribution of the thesis includes development of different computational meth-
ods that can successfully be applied to address the problems of off-targets effects at various
levels of system inference.
7.2 Discussion and conclusion
This thesis is focused on the development of in silico methods for prediction of toxic out-
comes. The thesis envisages a global view in response to toxicity profiles of chemical com-
pounds as well as local (specific) consideration on the mechanism and pathway level. For
example, a drug or a chemical compound might interact with a molecular target which can
result in interactions with multiple molecular targets including both therapeutic as well as
off-target with different affinities. In this process, consequently it can activate different sig-
naling pathways or interact with functional pathways. Additionally, such interactions at cel-
lular level can produce toxic effects on certain organs. This can be further extended to the
ADRs profile of population sharing similar toxicological pathways or network.
The study reported in the chapter 3 establishes a novel method for prediction rodent tox-
icity only available information of chemical data. Similarity method needs little informa-
tion to formulate a reasonable query; specifically nothing need to be known about the ac-
tive confirmation of the query molecule as its based on the 2D coordinates of the molecules.
Similarity-based model can be really useful when there is little or no information on the target
is known. Implementation of similarity method are computationally inexpensive and large
data sets can be predicted and analyzed in less time. A major limitation of this approach
is that prediction for each query (unknown) molecules depends largely on the activity and
diversity of the structurally similar molecules present in its training set which accounts on
the neighborhood behavior of the molecules. Though the molecules are compared using
structural molecular fingerprints, however the scoring is based on the global similarity be-
tween the compared molecules. Most of times it is observed that the property of a chemical
compounds is deeply connected with a local feature present in it. Hence, understanding
this local patterns is extremely important in order to understand the activity of a molecule.
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In this study, fragmentation approach was implemented inspired by the ’local feature based
association’ hypothesis. It was observed in this study, that addition of fragments based iden-
tification improved the prediction for the most toxic class I by 5 % , class II by 9 % and class
III by 3 % on cross-validation set as shown in table 3.3 . Based on only individual fingerprints
the prediction method achieved highest performance with ECFP4 , followed by a combina-
tion of FP24 and fragments and only FP24 fingerprints individually has the least performance
on cross-validation set. However, the best performance on external validation was achieved
by combination of FP24 and fragments. The ensemble method developed in this study was
compared with the commercial software TOPKAT and publicly available QSAR based method
T.E.S.T and have outperformed in all evaluation measures on the external set as shown in ta-
ble 3.3 .
Chapter 4 represents an ensemble model based on similarity and fragments approach was
developed to predict the toxicity of the chemicals by using concatenated ’FP24’ fingerprints
and statistically analyzed toxic fragments. The similarity approach is based on the neigh-
borhood behavior of chemicals compound and representation of their structural feature us-
ing molecular fingerprints. In the fragment based approach, each molecular structure was
compared to statistically analyzed fragments by using substructure search that represents
the presence or absence of particular toxic substructures in the molecules with a confidence
score. The application of this ensemble approach has the potential to achieve a classifica-
tion model with high prediction accuracy scores as well as prediction confidence. The major
advantage of this approach is the capability to incorporate addition of new toxicity data eas-
ily and developing models for other toxic end points. In this study, two different methods
were proposed for the prediction of interference of the Tox21 challenge data set consisting
of chemical compounds in two major biological pathways; nuclear receptor pathway and
stress response pathway. The data was generated in a standard uniform experimental setup
which serves as a gold standard data source for evaluating performance of different predic-
tion methods. In the first section, a similarity-based fingerprint method is reported which
is based on the ’ similarity property principle’ and concatenated fingerprints with molecular
descriptors based binary fingerprints. This method performed relatively better in combina-
tion of different fingerprints and descriptors. In the second section, machine learning based
models were developed in combination of individual fingerprints and as well as in combi-
nation with molecular property based descriptors. It is observed that the machine learning
models based on RF classifier achieved best performance when compared to other two ma-
chine learning models (NB and PNN) as well as the similar-based fingerprint method. The
superior performance of the RF models can be attributed to the different tunning parameters
chosen for individual targets (i,e RF algorithm is robust to different tuning parameters). On
the other hand, the poor performance of the PNN model can be explained by its strong in-
clination towards the majority class coverage of the training set. To understand this behavior
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in detail, the results were analyzed and it is observed that PNN models were able to correctly
predict all the true negatives in the external validation with a confidence score higher than
0.9 but failed to correctly predict the actives (true positives) for all the three targets. On the
other hand, NB models could predict the highest number of true positives with confidence
scores higher than 0.99 in comparison to the RF and PNN based models. However, NB lacks
the prediction ability when it comes to true negatives (inactives /majority class). Taking an
example of a result from randomly selected target ER-lLBD, this trend was analyzed in de-
tails for each models taking in consideration of two different fingerprints (MACCS; ECFP4)
as shown in table 4.16 . RF based models are able to identify the patterns associated with
respective classes in case of imbalanced data set.
Furthermore, it is toxicity alert encoded fingerprints (ToxPrint) as well as atom state based
fingerprints (EState) failed to obtain consistent performance across most of the targets for
various models. This could be due to the fact the chemotypes in the training set do not match
with the pre-defined toxicity alerts encoded in the ToxPrint fingerprints. On the other hand
the MACCS fingerprints encodes the similar substructures like the one present in the chem-
ical space of the Tox21 challenge data and therefore performed better and consistent across
various machine learning models. This supports the fact that prediction of toxicity can not
always be encountered using a global approach (i,e identification of presence of certain toxic
alerts in the chemical space). Target specificity and local substructures closely associated
with the chemical space addressed in the study plays an important role in the prediction
process. In addition, selection of optimal descriptors which could represent the chemical
space and an unbiased classifier which can learn the patterns and used this knowledge to
predict activity of an unknown compound is in real a true essence of predictive science.
Overall, in this study it can be emphasized that a simple RF based classifier consistently
demonstrated robust prediction for all the three targets. This method is relatively simpler
and computationally less expensive than other methods of the Tox21 challenge. The results
of this study are equally good when compared with the Tox21 challenge top models with
respect to AUC values and are better with respect to balance accuracies. This further adds
to the usability of the optimal method developed in this study. The methods will be pub-
licly available. In this study, a random forest based in silico toxicity prediction method is
reported, emphasizing the importance of predictive toxicology as a fast and reliable way to
predict the toxic outcome of chemical compounds. Additionally, it can be concluded from
the result of this study that the combination and application of RF algorithm and substruc-
ture based molecular fingerprints (MACCS) can be regarded as a very promising prediction
tool for evaluation of toxic effects of new chemicals.
In chapter5, a novel approach to detect fatty liver drugs using metabolic network based target
selection and computational molecular modeling method had been reported. The important
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targets that play important role in the fatty acid metabolism have been identified using the
kinetic modeling of the central hepatic metabolism. Out of the eight top ranked target, CPT1
was selected for further investigation and computational modeling studies. The inhibitors of
the CPT1 were selected from the chembl database (ref) and two different hypotheses were
proposed. First hypothesis was proposed to predict drugs that could bind to the malonly-
CoA binding site of the CPT1 and there by result in no beta-oxidation of the fatty acids. The
inhibitors of CPT1 liver isoform in humans were used to create common feature based phar-
macophore model. The inhibitors were obtained from the same source (tested in the same
assays) and therefore serves as gold standard to generate the model. All the inhibitors had
strong activity value as shown in the table 5.2, a close inspection of the structures of these ac-
tives inhibitors in the training set reveals all these compounds three common features such as
one hydrophobic group and two hydrogen bond acceptor lipid groups with an interfeature
distance less than 2.5 Å. On comparison of the functional groups of these actives sets con-
firms the carboxyl group which denotes the hydrogen bond acceptor lipid are important for
the interaction with the enzyme pocket. However, having heterocyclic ring in the structure
makes them hydrophobic and which is essential for it to be transported to the site of action
by diffusion across membranes. Additionally, it was also noticed that some of inhibitors of
the CPT1 have structural similarity with carnitine, supporting the second hypothesis in this
study is valid. The 12 known fatty liver drugs were mapped to the common feature pharma-
cophore model, out of which 5 drugs were mapped as shown in the figure 5.8 . Amiodarone
which is one of the classical fatty liver is also a inhibitor of CPT1, this supports the hypothesis
that drugs inhibiting CPT1 can results in fatty liver syndrome. Based on the pharmacophore
model 100 approved drugs were predicted to have similar pharmacophoric features like that
of CPT1 inhibitors with individual fit value. Top 30 drugs were selected having highest fit
value. It is commonly observed that binding affinity of drugs to the intended molecular tar-
get is much higher than to their off-targets. Therefore, it may be possible that drugs that are
administrated at higher doses at regular interval can induce fatty liver much faster that the
drugs that are taken for a short duration and in less quantity. So considering the daily admin-
istrative dose as well as therapeutic area, 23 final drugs were selected which are suggested for
experimental validation as shown in the table tab:pharmdrugs.
Molecular docking studies of the drugs predicted using the fragments and similarity search
method reveals that drugs can also bind to the carnitine-binding site of the protein resulting
in competitive inhibition. According to the second hypothesis, three drugs were predicted.
Since, the crystal structure of the CPT1 was not available, the structure of human CrAT pro-
tein was used for molecular docking studies as shown in the table 5.9. One of the main short-
coming of this investigation is unavailability of the CPT1 structure, it is therefore difficult
to predict how exactly the carnitine similar analogues can bind to CPT1 in a real biological
system.
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As illustrated above, the approach presented in this chapter is a novel way to determine tar-
get, drugs and the mechanism involved in drug-induced fatty liver syndrome. The unique-
ness of this approach includes the consideration of different layers of information: selec-
tion of targets using a kinetic model of the central hepatic metabolism, generating of models
based on the pharmacophores as well as ligand-protein interaction. Beyond the prediction
of potential target for fatty liver and the mechanism involved, the modeling approach pre-
sented in this study is expected to open up many additional exciting possibilities in the near
future, for e.g data on drugs-target interactions may be integrated with the kinetic model to
further enhance the model’s accuracy. The combination of computational system biology,
structural bioinformatics and cheminformatics based approach as presented in this study
could become indispensable tool during the pre-clinical and clinical phases of new-drug de-
velopment for studying the nature of adverse side-effects.
In the study reported in chapter 6, it was possible to established an in silico screening proto-
col taking into the structural similarity measure, pharmacophoric features and supported by
computational validation which lead to the identification of novel binding of antiviral drug
acyclovir to peptide binding groove of HLA- B*57:01 molecule.
Identification of drugs candidates associated with IM-ADRs is an important step in drug de-
sign and development. Peters and group 107 recently proposed a novel mechanism through
which abacavir interacts with HLA- B*57:01 molecule leading to an alteration of the speci-
ficity of HLA- B*57:01 for self-peptides and associated immune mediated T-cell hypersensi-
tivity reaction . This hypothesis is termed as ’altered self-repertoire’ hypothesis. In this study,
this hypothesis was used to screen drugs that could have potential effects on the self-peptide
repertoire. In silico prediction method was developed considering abacavir as the lead struc-
ture and to predict drugs that are structurally similar to abacavir. Since, the crystal structure
of abacavir-HLA- B*57:01 complex was available, screened drugs were further investigated
based on molecular docking experiments. Six drugs which were structurally similar to aba-
cavir and one drug (minoxidil) having similar pharmacophoric groups but structurally less
similar to abacavir; were suggested for in vitro experiments. Of the panel of seven drugs
tested in the in vitro studies, acyclovir was found to have the strongest effect and alter the
binding specificity and ligand repertoire of HLA- B*57:01 molecule. This effect produced by
acyclovir was in a qualitatively similar manner as abacavir, however quantitatively to a much
lower degree. Acyclovir is structurally similar to abacavir is also a guanosine analogue and
share a Tanimoto similarity score with abacavir above 0.80. They both are from the same
therapeutic area (i.e antiviral agent). In the in vitro experiments, quantitatively the presence
of acyclovir led to 2-3 fold increases in binding affinity as measured in IC50 where as abacavir
led to a 1,000 fold increase in IC50 values for individual peptides and large number of pep-
tides presented exclusively in the presence of the drug. Acyclovir have a safety profile and the
Chapter 7. Summary 94
effects of the magnitude observed here are below the threshold to induced IM-ADRs. How-
ever, this study establishes a first estimate of a threshold of what can be considered a safe in
the experimental essays.
7.3 Limitations of the methods presented in this thesis
Structural-cheminformatics based studies are highly reliant on the existing data. The meth-
ods reported in chapter 3, is based on the chemical structures similarity. This makes it com-
pletely depended on the chemical space used in the study. The performance of the individual
toxicity classes are dependent on the available data eg. toxicity classes (III , IV, V) had better
prediction when compared to toxicity classes (I, II, VI) which had limited data. Toxicity pre-
dictions from chemical structure is only possible, when the structures are directly connected
to know mechanism of action. However, if the toxic effect is the result of several different
mechanism working sequentially or simultaneously, then the reliable prediction based on the
chemical structure could be difficult. The study can only predict the presence of structural
alerts in the compound, further investigation regarding the biological processes is required.
In chapter 4, the machine learning methods are highly dependent on the data set. The molec-
ular descriptors selected in the method development was based on defined chemical space
for specific targets. Moreover, the imbalanced data set is another limitations in order to in-
crease the predictive performance of the models.
Chapter5 represents a novel approach to understand the mechanism involved in fatty liver
disease, however the nonavailability of the crystal structure of the CPT1 makes it impossi-
ble to study in details how the suggested drugs will bind to the CPT1 in a biological system.
Therefore, lack of data forms a limitation on the applied methods by reducing the applicabil-
ity domain of the generated models.
In chapter 6, the identification of novel binding of antiviral drug acyclovir to peptide bind-
ing groove of HLA- B*57:01 molecule was discovered. This supports that the drugs from same
therapeutic classes can have similar biological activity. However, acyclovir could not produce
hypersensitivity reaction as it is in case of abacavir. Further studies are required to investi-
gate what kind of functional groups present in abacavir, upon interaction with HLA- B*57:01
molecule; produces T-cell response. This will help to identify more drugs in the same or dif-
ferent therapeutic class, that can bring the similar adverse drug reactions.
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7.4 Perspectives and future work
As highlighted in previous chapters, the methods developed in this thesis has proven as valu-
able supplements to investigate the toxic response of chemical structures. Given the chal-
lenges the regulatory toxicology is currently facing (as explained in chapter3 and chapter4)
applications of methods developed in this thesis might prove useful when deciding which
chemicals to test thoroughly in classical toxicity test and which end points to investigate.
Additionally, the hypotheses proposed in chapter 5 to explain the underlying mechanism be-
hind drug induced fatty liver will help to design better drugs that could avoid such off-targets
effects; or help to understand how particular drug-target interactions in a metabolic network
can result in metabolic syndrome. In chapter 6, a new threshold was defined to predict the
drug induce ADRs related to specific HLA alleles, which can be useful in the process of HLA
testing.
These methods can provide the predicted toxicity profiles of the unknown chemicals, that
can be later validated in vitro. Once the actual profile established this information can be
integrated into the in silico model.
Finally, there is certainly a need of monitoring of predicted off-target effects of drugs or chem-
ical structures,on a more dose dependent manner, such as in what concentration of the drugs
such off-targets effects are triggered. Thus, supporting the saying of Paracelsus that ”Poison
is in everything, and no thing is without poison. The dosage makes it either a poison or a
remedy”.
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Appendix A
Software and databases
Different open source as well as commercial softwares used in this thesis are acknowledged
in this section.
Name License Original language Links
Open Babel Open C++ http://openbabel.org/
JChem Academic Java https://www.chemaxon.com
MyChem Open C++ http://mychem.
sourceforge.net/
KNIME Open Java https://www.knime.org/
Discovery Studio Commercial NA http://accelrys.
com/products/
collaborative-science/
biovia-discovery-studio/
GOLD Commercial NA http://www.ccdc.cam.
ac.uk/solutions/
csd-discovery/
components/gold/
PyMOL Academic NA https://www.pymol.org/
Additionally, the databases used in the different projects reported in this thesis are men-
tioned.
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Name license links
PubChem Open https://pubchem.ncbi.nlm.nih.gov/
ChEMBL Open https://www.ebi.ac.uk/chembl/
PDB Open http://www.rcsb.org/pdb/home/home.do
ZINC Open http://zinc.docking.org/
SuperToxic Open http://bioinformatics.charite.de/supertoxic/
DrugBank Open http://www.drugbank.ca/
PubMed Open http://www.ncbi.nlm.nih.gov/pubmed
LiverTox Open http://livertox.nih.gov/
KEGG Open http://www.genome.jp/kegg/
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